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Abstract 
Background: The study was prompted by nursing concern at St Francis Hospice that, in HIV-
positive patients, the use of opioids for symptom·control may shorten life, while I felt that pain was 
not recognized and therefore analgesia was withheld until the HIV·positive patients were close to 
their natural death. 
ObJective: To compare pain control and sedation practices for terminally ill patients with HIV or 
cancer. 
Methods: This was a retrospective case-control study. Cases were consecutive deaths related to 
AIDS in St. Francis Hospice, Port Elizabeth, South Africa from August 1998 to December 2001. 
Controls were cancer patients matched for race and socio-economic circumstances. 
Main Findings: 
Five days before their day of death, 3 of the 29 (10%) AIDS patients were given morphine for pain 
control compared with 20 of 29 (69%) cancer patients. On the day of their death 17 (59%) AIDS 
patients were given morphine compared with 25 (86%) cancer patients (p< 0.5). 
Eleven (65%) of the 17 AIDS patients who were given morphine died within 48 hours of its 
commencement. The maximum daily dose was 50 mg per os, which is within the recommended 
starting dose range for opioid naTve·patients. 
In the last 24 hours of life sedation was administered to 7 of the 17 (41%) AIDS patients on 
morphine and 2 of the 25 (8%) cancer patients on morphine (p=0.01). The dosages administered 
were within the lower therapeutic range. 
Twenty AIDS patients had pain recorded on admission with only 11 (i.e. 55% of those with pain) 
receiving morphine. This compares to 12 patients with cancer who had pain on admission, with 
100% of these receiving morphine. 
Interpretation: There are statistically significant and clinically important differences in morphine 
administration between AIDS and cancer patients. Care for cancer patients was similar to accepted 
best practice where between 70 and 89% of cancer patients near end·of·life receive morphine. 
AIDS patients are probably receiving inadequate pain control: in services offering "best practice" 
palliative care about 80% are treated with morphine in the last few days before death. 
jj 
The doses of morphine and sedatives given to the AIDS patients are too small to have contributed 
to their death. A possible explanation is that pain as a symptom was not recognized and therefore 
not treated timeously in the majority of AIDS patients. 
iii 
Summary 
Background: Reports in the literature abound that pain is under-recognized and under-treated in 
AIDS patients, whether ambulatory, hospitalized or terminal. This study was prompted by local 
nursing concern that in HIV-positive patients, the administration of opioids for symptom-control may 
shorten life: "They die within 2 days of you starting him/her on morphine.· I felt that pain as a 
symptom was not recognized, and in consequence analgesia was being withheld until HIV-positive 
patients were close to their natural death, thus denying them adequate pain control. This is out of 
keeping with palliative care values as defined world-wide. 
Objectives: To compare pain control and sedation practices for terminally ill patients with HIV and 
patients with cancer. 
Setting: The 6 bed in-patient unit of St. Francis Hospice, Port Elizabeth, South Africa. 
Methods: This was a retrospective case-control study. Cases were consecutive deaths related to 
AIDS from August 1998 to December 2001. Controls were cancer patients matched for race and 
socio-economic circumstances. There were 29 people in each group. All 39 patients who died in the 
in-patient unit with AIDS or complications related to AIDS were identified. Ten people were 
excluded from further analysis: 7 had both AIDS and cancer, 1 died from causes unrelated to AIDS 
(gunshot), and records were unavailable for 2. For the remaining 29 AIDS cases, 29 cancer controls 
were selected by identifying the first HIV negative patient to die in the in-patient unit from cancer 
who was of the same race, had similar socio-economic status, and had complete records. 
Clinical history, progress, mode of deaths, and use of opiates and sedatives were extracted from 
the charts of study subjects. 
Hypotheses: 
1. For some AIDS patients death is possibly induced or hastened by administering opioids. 
2. Some AIDS patients die without adequate analgesia as too little is administered too late. 
Main Outcome measures: 
1. Total numbers on morphine: Five days before their day of death (D-5), 3 of the 29 (100/0) 
AIDS patients were given morphine for pain control, receiving on average 120 mg per 24 
iv 
! 
• Symptom prevalence on admission to the in-patient unit in patients who were not given 
morphine 
The doses of morphine and sedatives given to AIDS patients were within the normal therapeutic 
range and thus were unlikely to have contributed to their deaths. 
Morphine use in "best practiceD palliative care services is reported to be between 70 and 89% for 
cancer patients near end-of-life and up to 82% for AIDS patients near death. During the time of the 
study pain was not treated timeously in AIDS patients in the St Francis in-patient unit. By the end of 
the study, morphine was being administered substantially more frequently than at the start, but 
there were still AIDS patients who had significant unrelieved pain and distress during the last 6 days 
of life. Sedatives were predominantly used in a subgroup of AIDS patients who received morphine 
for less than 24 hours preceding death. And this suggests that inadequate symptom-control led to 
the inappropriate use of sedatives. 
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Chapter 1 Introduction 
Death is a constant ingredient of the human condition. We may try to prevent, delay or cheat it, but 
it eventually overcomes every one of us. Pain is another persistent ingredient of our human 
condition and death is often associated with pain. Pain may be the oldest symptom facing humanity. 
From the primitive medicine-man or shaman at the dawn of health care there has been sufficient 
time for pain as a symptom to be conquered. In 1990 the WHO declared war on the pain associated 
with cancer. Yet, today pain associated with AIDS and other terminal conditions remain a major 
public-health problem even though its causes are clear, its pathophysiology somewhat understood, 
the way it thrives in poverty and disadvantaged groups is known, and the public can be educated 
about it. 
1.1 Developing an idea and motivation for the present study 
What prompted the idea for the study were informal remarks made by some of our nursing staff that 
strong opioid usage accelerates death in the HIV patients managed at St. Francis Hospice. "They 
die within 2 days of your starting them on morphine- was a comment frequently reiterated by some 
nursing staff. 
This opinion is questionable. There are several articles in the literature that specifically address the 
general fear of hastening death by prescribing pain medication. 2S. SI. 7S A number of studies provide 
evidence that pain is under-treated in AIDS patients in general. 10, 43. 41, 47 Several articles discuss 
barriers to pain relief. '0 21. 37, 78 In South Africa a common attitude towards caring for AIDS patients 
is that "nothing can be done-: few investigations are requested as resources are scarce, laboratory 
tests costl~3. and little treatment is available in the public health sector.31 The Integrated 
Community-based Home Care Project in Port Elizabeth28 makes little prOVision for direct patient 
management by a medical doctor. It is essentially a nurse driven initiative, utilizing and supervising 
informally trained volunteer community workers, which supplies a much-needed service, but is 
unable to provide significant diagnostic and medical symptom management or physician input. 
During this study, doctors were available for consultation with the managing nursing sister in a 
remote consulting capacity but personally they did not see and assess significant numbers of 
patients in the Community-based Home Care Project. 
16 
Another difficulty is how to decide when AIDS patients are terminally ill. With prompt diagnosis and 
treatment of an easily reversible opportunistic infection, the clinical picture of an AIDS patient can 
change dramatically.41.1i2 
This combination of factors could put AIDS patients at a disadvantage compared to cancer patients 
with respect to appropriate care and symptom-control, including adequate analgesia and sedation. 
Although the nursing staff may suspect that AIDS patients die because of the opioids that were 
given, an opposing opinion is that analgesia was withheld until they were close to their natural 
death! St Francis hospice's logo is "No end to care" and they subscribe to the general principles of 
reducing suffering as defined in their mission statement. 
Neither outcome described above is in keeping with palliative care values as defined wOrld-wide.2o. 
80 On the one extreme, death will have been hastened (although unintentional if it did occur as a 
result) by giving opioids. Towards the other end of the spectrum, relief from pain was not prOVided, 
defeating the goals and principles of palliative care. 
The central issue is management of pain. The 2 opinions are wide apart on the spectrum of 
approaches to pain management. They are so wide apart that they can be seen as opposing views. 
No records are available that reflect the actual situation. This leaves a wide area open for 
investigation and a need for objective evidence that will as accurately as possible provide clarity. 
My aim is to analyze retrospectively clinical records to determine the patterns of strong-oploid 
administration during last few days of life by HIVIAIDS and cancer patients cared for by St. Francis 
Hospice. From this analysis I hope to obtain objective evidence to encourage an effective palliative 
care attitude towards dying patients by recognizing and overcoming barriers that may exist. 
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1.2 Research statement! question 
Does opioid administration during the last 6 days of life differ for HIV/AIDS patients in comparison 
with oncology patients in the in-patient unit of St Francis Hospice? 
1.2.1 Purpose 
• The study will quantitatively describe opioid administration during the last six days of life 
with the aim of determining whether differences of usage exist between cancer and AIDS 
patients. 
• Critical evaluation of the gathered information will attempt to identify patterns and quantify 
the differences, if they exist. 
• It may suggest ways to further assess, address or explain differences. For example, 
attitudes may change when made aware of differences or methods used by clinical staff to 
elicit symptoms may improve. 
• It may also contribute to ideas for further studies that may attempt to clarify underlying 
reasons for the findings. 
• Deficiencies in the data in routine patient records, if found, will be documented and 
suggestions for improving information necessary for patient care, clinical audit and research 
may evolve. 
1.3 Abbreviations used 
AIDS - Acquired Immunodeficiency Syndrome 
HIV - Human Immunodeficiency Virus 
PO - Per os 
prn - as requiredl needed ("pro re nata") 
SC - subcutaneous 
WHO - World Health Organization 
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1.4 Research design and methodology 
This was a retrospective, case-control study evaluating opioid administration to terminal AIDS and 
cancer patients in the 6 bed in-patient unit of St. Francis Hospice, Port Elizabeth, South Africa. 
Objective evidence was gathered from the two parallel groups of patients to evaluate the situation 
objectively. 
Cases were consecutive deaths related to AIDS from August 1998 to December 2001. Controls 
were cancer patients matched for race and socio-economic circumstances. There were 29 people 
in each group. All 39 patients who died in the in-patient unit with AIDS or complications related to 
AIDS were identified. Ten people were excluded from further analysis: 7 had both AIDS and cancer, 
1 died from causes unrelated to AIDS (gunshot), and records were unavailable for 2. For the 
remaining ·29 AIDS cases, 29 cancer controls were selected by identifying the first HIV negative 
patient to die in the in-patient unit from cancer who was of the same race, had Similar SOCio-
economic status, and had complete records. 
Study subjects charts were reviewed for clinical history, progress, mode of deaths, and use of 
opiates and sedatives. 
1.5 Outline 
A review of the literature was summarized in the context of the problem formulation. 
Key concepts are defined in chapter 2 for clarity of interpretation of the findings within the present 
understanding (framework). General concepts such as palliative care, suffering, pain control, 
adverse effects of opiolds will be discussed as well as more specific concepts such as the definition 
of advanced AIDS, the decision on when to institute palliative care for AIDS, pain and AIDS. 
An overview of the research design and methods applied will be given in chapter 5. The description 
of the methods will include variables, data-capturing and editing as well as short-comings and 
sources of error. 
The results and analysiS of data (chapter 6) will be discussed and displayed in tables and graphs 
after which main findings will be summarized and discussed (chapter 7) within the broader 
framework of palliative care before final conclusions will be formed and implications be considered. 
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Chapter 2 Theoretical Framework 
2.1 Introduction: demarcating the literature covered 
A literature search was done using MEDLINE and AIDSLlNE: Numerous complete journal artides 
were available in electronic format thanks to access through a -log in and password system- at the 
University of Port Elizabeth Library. The search was concentrated on studies pertaining to 
symptom-control during the last week in life of AIDS and cancer patients. Key words used were 
combinations of AIDS, pain control, end..of-life, last week. palliative, terminal. Few artides were 
found. especially about AIDS patients. and the search was broadened to include symptom 
prevalence and management in the terminal phase that encompasses a period of more than a 
week. 
To put the study in context of a palliative care setting. general palliative care references were 
consulted as well as a study of home-based care for AIDS patients in which St. Francis Hospice is 
participating and following defined guidelines for the care of people with AIDS patients. 21 During the 
course of assimilating and writing the dissertation. a number of resources on research methods and 
statistics were consulted. 
• AIDSLINE no longer available on the intemet. 
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2.2 Setting and context 
1HE GOAlSoJ' HOSPICE 
'" To care humanely for the terminally tn. 
• To p~~ iO{ the physical. ~motiQru.l.~aJanc1. 
spiritual needs of the patients as' well as those of 
their tovedones. 
'" To give to famIlY 81'1d friends tneapportunity 19 
share actively in. tbe care, comfort and support of 
the dying person, 
* To make the patient's final days as painless and 
meaninatul as pass-ible. 
Figure 1: The Statement of Service offered by St. Francis Hospice 
St. Francis Hospice has a 6 bed in-patient unit. Annual totals for in- and out-patients cared for 
during the study period ranged from 664 to 1080. Yearly admission statistics are available since 
2000. The average admiSSion rate is 21.5%; i.e. The admission rate varies, and between 18 and 
30% of registered patients are admitted to the in-patient unit during the course of different years. 
From the admission-book, 22 and 24 AIDS patients were identified that were admitted for AIDS-
related problems during 2000 and 2001 respectively. The proportions of admissions for AIDS 
patients and cancer patients are not available from the recorded data, but it seems that the 
admission rate for AIDS patients is substantially less than that for cancer patients. 
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AIDS Cancer Totat 
In.pallenl Admission 
patients patlef'\fS Pallt!flIs 
Unit rale (%) 
Admissions 
0311998 to 02119&9 71 (1 2%) '" ... ru. ru. 
03/1999te 02l2(l()O 155~25%) '" 776 238 '0% 
03/2000 10 0212001 221 (32"') '" '" '" ". 
0312001 Ie 0212002 533 (~9%) "7 "., '" ". 
hbte I : Pa tiMI numb",.. cared Ie. al SI. Franci. Hcsp'e. 
There are no statist ics avadable Ind.ca1 lng Ihe proportIOn of pat len1s who died In the ,n -patient un it 
an<! those who were dIscharged home 
2.3 Definitions of concepts 
2.3.1 Palliative ca re 
The World Health Organ lZ3t.on" oellrles oan'atlve Care as' Ihe active tolal care of pa~ents whose 
oisease 's fIOl respons"'e to Cu ratllle 1featment Control of oa.n, of other symptoms, and of 
psyd101o~ocal SOCial and SII",\Ual problems, Is paramount The goal of palil aloVe care is 
ach ievement of the best qua illy 01 li fe lor patients and the" families ' 
PallialiVe care" 
Afrorms li fe and reQ3rds dyong as a normal process 
Neilher hastens nor postpones dealh 
PrOVides rehef from paon ane other distressing symptoms 
Integrates the psychologrcal arid sp,(rtual aspects of care 
Offers a support system 10 help patients love as aClively as poss l ~e un," death 
Offers a support syslem to help patients' fam,l,es cope during and after lhe patlenl s Iitness 
A l)'plcal hospice pal~ali \le care serv ices In South Africa focuses mamly on home care It also 
Includes In parient UnitS in selected hospices accOrding to ava,labilit~ 0' reSOOrCeS 
The Hospice ASSOC iatIOn of South Afnca cl",ms that hospices are the on ly faCilrues In South Africa 
that provide oani~",e Care as defined accorllonglCllhe WHO 
2.3.2 Totailuffering 
", 101:\11 on qll9lity 01 life leads InexOl'8b/)' to related islUM that ilra conlribltbng to wlfering ThIs 
~d&I conlld&ration ot r~;IItion'h;PI. contidentlllllty. Spitrtuallty sympll)ms and their management. 
reMobi'oilation. rights Ind rflponl,I)IM". &rid ~e's relationShip WT1h!helI God. 
Sulfe"IIII" a complex muMactorl81 enhty· Contribullf'9 tauS" can be alqlfHSed as 
Pain 
~ ohytoeal .ymp!oml 
+ psychologICal conftiell 
• IOClal d,lflcuilifl 
+ eu~urallaetor. 
• spiri~ tooeemtl 
• T 0181 tuffeflng 
Filiure 2: Total .ulf.rlI>g 
All pa~an!s w~h ;II wmlNlllIMu eJlptlience tull'.-.ng 10 
a greatar Of IoKler degree The oombirlallON 01 f-=1Or1 differ belweel'l each patient Tile 
mulbfac!OI)III nature 01 sull'er.Ig is Ihe reason why MIIeraI 1act0f1 mlluence the management 01 
pan. and aTs{) why ;II mulld!scipIinary approach is required. 
Dunng paItiawe care !he goals of tteatmf!lll shills from proIongmg surv .... allO opllmizlngluncliorls 
sod laler to oplImlZl."9 eomlOfl As the goals 01 prolonging Ina and funetion be<:ome liltfaasingly 
unachievable. pnoritIes ~ It i5 importanl to recogniul and respectlhe proOI'lII" oIlha pat>ent in 
prefarence 10 the care team ¥1 enabling !he patient to maka intOfmed decisions about tllt!l"'peutlc 
''P'.'' 
" 
2.3.4 Pa in contro l 
2.3.4.1 Basic principles of effective pain control 
PaIn .$ II multKllmenSlOllal construct 
A ctos"'pllned munod."enSlOOal assessment tS essemlal Th" ,nc ludes address,ng 
revers 'b~ causes 
AvOId delay 1(1 treatIng 
Communicate Wllh the palten!, famlty and Olher careg IVers 
Follow a stepped approach thai depends on sever,ly and cause of paon (ThIS reqUItes earty 
formal assessment, wh ICh al present is not 100000porated "'10 51 F.ancrs home care 
prOjecl) 
• ConStant paIn requIres regular admin,Slla!ion 01 analgesICs 
Always leave ,nstructoans for a 'breakthrough dose-
COnSider opioods as only one part oilll!! management ot IOtaI pan 
Pat ients w,th rapld l1 chang,ng cllnocal ClfCumstances requlfe ongang assessments 
2.3.4.2 Assessment o f pain 
Failure 10 assess paon can lead 10 !est t/'lan OpImal paon conlrolior the pallen! 
Assessments SI'lO\,lId (lC(.ur 
AI regul3r Intervall after InltJlltJOn of the Ireatment 
At eac/l .- report 01 pain Of change on qua..lyfOfllens,1y 01 palO 
AI a tu!\able Inlerval all&! pharmacologlC8l Of non-pharmacologocalll1!el\lentoom 
The P of tne lnobIII assessment IS 10 charactel'l;ze the pan by 1ocaI1OfI, In!eflS'ly and aelK»Dgy 
EssentIal to lhoe ""WOI aS$eslmeni$ are 
A de!alled hIStory 
A phYSICal ewamlflatoon lI'ICIvdong neurologcal 
A pSyehosoclalessessment 
A o:ItagnosllC evalualIOfI OlSease modifying ltoerap_ may contribute 10 managing pam 
2.3.4.3 4 steps of cancer pain assessment: 
Step 1 Assess whether \he paon IS beong produced by d'rect or ind irect tumour wwohlement. 
eancer treatment or whether" 15 unrclated!O lIIfltumour and treatment 
Step 2 T.eMment 01 Ltle conc""e'" .,fe<:tJor!s may resu lr III more etf(!ct,ve pa," re lief lhan 
ger>eraf measures alorle ' " IFor AIOS pal!ents pa,n Can be caused by dama~ from 
HIV IIlfectlOl'l, c()-Infedons or tumours, treatmenl (ann_T B Or antl.ret rov"~I), or 
unrelated d,seases I 
Step 3 Measure the Intensrty of pain and other symptoms 
a Example 0/11 Vrsual Analogue Scam (0· 10 em'" 
,---------------------" 
e WisconS/n aner p,,,,, /rIvenrory" 
Step 4 A,~s!he mu'bple dim6"lSIOns 0I1he e>1)fe5S'OO or paWl 
Step S ldenbty poor prognosl!C: factors lor pam control 
A nUfse at SI Franet5 record the presence 01 paon on a" 'tern sca!e 
1 Map' problem 2 MInOr problem 3 Nola problem 
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Went Possoble P8U1 
4 No! known 
ST 1--H"''1C1S IIOSPICE 
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a Sloop C. Mobihty & Ac tIVIty 0 Rl'la"YC5 VIeW. 
r ~llre J Medica l admISsIOn. sheet preilefll!y used 51 FranCIS "<:lsp« 10< l1li palle<1ts 
2.3.4.4 Analgesic use 
Pain control is one 01 ttle IlIOSI/mporlalll aspe<:is o! ef"(I.oI·!,!e care" .. " 
Cho4(;e 01 drug 
Hied II drug appropoale!or the type 01 pili" 
se1ecIa drug appropfiate 101' lhe seventy or peLn 
U$e combmatlons of dr"lll , not com~'ned oreparuons 
lolow the "arnllgM<: ladder" 
• neve< use a p!acetlO 
The anatgeslc ladder 
• If the prlncr lOed drugs do nOI produce adequate anatgesL' lrealment ill MCalaled in an 
(l(dertv manoer 
from non-oorord 10 weak 01llOld 10 lUang oprotd tIS "st/llted in IN! World HaaM 
Organllalton s "An8ige!.IC l aOder" 
nor\·oplOld analgesIC should be eonhnued wilen oprOid drugs II le commenced a5 therr 
ac:tton can be complementa~ and.fIow lesse< doses 01 oprordS 10 be 8dm'Mtered 
adJuvanl .".!ge$Cs ShOuld be admitllSlel'ed whenever 'ndicated 
27 
Analgesu On'll of C hoor:e 
SI~IP .... Non-orMOoCI to aclf.NMII ,.- ""'" 
S/o!p 2 P .... ~ Of Weak opoood. non- -• __ n opoood ..... ...-
SIeP 3 Paon per$IIta Of SIrOn!I 0j>000d '" non- -~ _.an opiood .~n\ 
Table 1: WHO ..... Ionic 1._. 
2.3.4.5 Escalation steps for morphine 
0_ Rout" Dosage $teps '" opiOt<l naIve pa~e<1llevery 4 roours) 
PO 5 10 " 20 30 ., 60 80 100 130 160 200 250 300 Morphne sc 25 5 " 10 " 20 30 ., 50 " " 100 "5 '" 
Atlmio·ster a bleaklhroug/l medicatiOl1 dose COIlsrslll1g of 50·100% of the 4·hourty doSe up 
to I hour from time of dose pm 
Progress \0 me ne~l level of the prolOCOl up 10 on<;e per 2. hours II [)aIf\ nol contlOlled 
Coot.llue otller modalrtie!o 01 tre8lment. ~"'9loca1lherapy for regoonat pail'll 





SedalJoo drowSiness confus'cln, nar<:OSlS. coma 
Dysphona. psydIomlmeu::: effe(:1$ 
Myoelonus 
"_ 
Nausea and vomiting delayed ga5tr1(: errtOlyftg. 
conSILpallQn dry mouth 
B4i<1ry colIC 
Resp.nnory depre5UJ1l 
Suppresu)n of cough 'eflex 
PoStilfltl hypotension 
Urgency, retention 
Ftuahk1g. 1WUting, prurltul 
Tabl. 4 Common .1Iv .... en.c .. 01 "";0;'" 
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Side-effects that may hasten death are: sedation and respiratory depression. 
2.3.5.1 Sedation 
Sedation usually accompanies the commencement of morphine therapy. It is usually mild and lasts 
from two to fIVe days whereafter much tolerance emerges. When severe drowsiness occurs, other 
causes such as metabolic disturbances, infection, cerebral mass lesions and other drugs should be 
excluded. Patients at risk are: 
• Elderly and frail people 
• Renal and hepatic impairment 
• Other causes of central nervous system depression, including drugs 
• Opioid narve-patients 
• Patients with only mild pain 
• Patients whose pain has been acutely relieved by a procedure such as a nerve block. 
The use of sedatives concomitant to morphine use, may enhance sedation. 
2.3.5.2 Respiratory depression 
Because respiratory depression is potentially life threatening, it is considered the most serious 
opioid side effect and is of great concern to doctors and nurses. Opioids can depress both the rate 
and depth of respiration. Although respiratory arrest is possible, it occurs in combination with mental 
clouding and somnolence, allowing for a reduction or discontinuation of medication if these 
symptoms develop. An excessive dose can, of course, cause respiratory depression. Patients in 
pain also respond differently to opioids than do persons without pain. Pain acts as a natural 
antagonist to the respiratory depressant effect of opioids. As pain increases, the level of opioid 
necessary for relief goes up, and so does the tolerance to respiratory side effects. Opioids 
beneficially overcome the oxygen hunger of patients who experience prolonged shortness of breath. 
2.3.6 Using sedatives during opioid therapy 
The indications for administration of sedatives in palliative care (and other drugs that have sedative 
effects) are numerous. During the terminal phase common indications are anxiety, intractable pain, 
massive haemoptysis, respiratory panic and terminal agitation. 
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Sedation Goals are: To achieve a peaceful death by: 
• decreasing uncontrollable suffering 
• decreasing fear 
• improving family support 
• reducing risk of accidental injury 
Ideally one strives for a level of consciousness that allows for meaningful interaction with the family 
for as long as possible whilst reducing suffering at the same time. 
2.3.6.1 Relationship between sedatives and hastened death 
Benzodlazeplnes: In St Francis Hospice midazolam is the most frequently administered drug for 
sedation near end-of-life. Other alternatives are Diazepam and Lorazepam. 
• Significant respiratory depression can occur with benzodiazepines in patients with chronic 
obstructive pulmonary disease and sleep apnoea - especially with parental midazolam. 
• In hypovolemic states, congestive cardiac failure and other conditions that impair 
cardiovascular function, benzodiazepines may cause cardiovascular depression. 
• Concurrent administration of opioids enhances sedation. 
• Abnormal liver and renal function frequently jeopardizes the elimination of drugs. Patients 
are at greater risk for drug toxicity and side effects. 
Neurolepllcs: Neuroleptics have several uses in palliative care. 
Where there is a legitimate concern regarding respiratory depression or compromise, classical 
neuroleptics are safer than benzodiazepines as anxiolytics. They also have anticholinergic side-
effects which may be useful in the terminal phase (aid in secretion control). 
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2.3.7 Hastening of death 
Hastening of death can de divided into two categories according to intent. If the intent is to hasten 
death, it is called euthanasia. The term "principle of double effecr is used26 to justify the 
administration of medication with the intention to relieve pain or other symptoms even though it may 
lead to the unintended, although foreseen, consequence of hastening death by causing respiratory 
depression or other vital organ depression. 
The principle of double effect has its origins in Roman Catholic moral theology. In the paradigm 
case, although a doctor is not allowed to directly abort a fetus (even to save the life of a woman), a 
doctor is allowed to remove a diseased and life-threatening uterus containing a fetus. Although the 
doctor expects the death of the fetus, he does not intend to kill it. Applying the principle of double 
effect to the use of pain medication, the good effect (pain control) is intended, whereas the bad or 
secondary effect (hastening death) is foreseen but not intended. 
The belief in double effect affects the care of patients and results in under-treatment of physical 
suffering at the end-of-Iife. Twycross76 found that "The use of morphine in the relief of cancer pain 
carries no greater risk than the use of aspirin when used correctly" [emphasis in the original]. 
Rather than hastening death, "the correct use of morphine is more likely to prolong a patient's life 
..... because he is more rested and pain-free. " 
In a study at Serei hospice, Japan, Morita" found that a combination of high dose opioids and 
sedatives used for symptom-control in terminally ill patients in the last days of life are not associated 
with reduced patient survival. The median midazolam dose was 40 mg per day 
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2.3.8 Advanced Acquired Immunodeficiency Syndrome 
In 1999 South Africa achieved the status of being subjected to the fastest growing HIV epidemic in 
the world. Educational efforts aimed at reducing the spread of HIV by changing behaviour have 
failed dismally and health care services, undertakers, family and relatives to name a few are 
experiencing the result. For every person who dies, many relatives and loved ones are left behind, 
in mourning. The number of deaths of young people is increasing with its accompanying grief and 
mourning. Children are being orphaned; elderly parents are left with added burdens of care. To add 
poor symptom-control to the already heavy burden, increases not only the discomfort of the dying 
person, it also increases the chance of complicated grief for those left behind. 
This is a time that presents opportunities for palliative care teams to significantly contribute to 
reducing the combined symptom burden and subsequent burden of grief of AIDS patients and their 
relatives by ensuring that our teams live up to the standards of palliative care as set out by the 
WHO. 
2.3.8.1 Staging Criteria for HIV patients 
HIV has become one of the best-measured chronic illnesses of our time in first-world countries. 
Accurate laboratory tools are available to use as objective measuresl3 , in addition to physical 
examination and symptomatology, for prognosis and outcomes, as well as for defining decision 
milestones. 
2.3.8.1.1 CD4+ count is useful for 
• Staging HIV infection, with resultant guidance for treatment decisions. 
• Response to antiretroviral therapy. 
• Establishing a differential diagnosis of opportunistic infections in symptomatic patients. 
2.3.8.1.2 Viral load is useful for 
• Prognosis, determining success or failure of antiretroviral therapy. 
Unfortunately CD4+ counts and viral load are beyond the health budget of the public sector and 
therefore not available to the majority of patients or care teams.33 A vexing question in a resource-
poor country is how to determine the stages of AIDS progreSSion, and for palliative care purposes 
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the end stage, without laboratory markers. Past history, symptomatology and physical examination 
are the key to the answer when laboratory markers are unavailable. 
When CD4+ count is not available, the WHO Staging System allows stratification of individuals" 
into four prognostic categories based on clinical criteria combined with performance status. 
2.3.8.2 WHO Staging System for HIV Infection and Disease 
Clinical Associated condition Perfonnance scale 
Stage 
1 0 Acute retroviral illness Scale 1 
0 Asymptomatic Asymptomatic 0 Persistent general lymphadenopathy Normal activity 
2 0 Weight loss, < 10% of body welght Andlor scale 2 
0 Minor mucocutaneous manifestations Symptomatic 0 Herpes zoster within last 5 years 
0 Recurrent upper respiratory tract Infections Normal activity 
3 0 Unintentional weight loss (> 10% body weight) And/or scale 3 
0 Diarrhoea or fever> 1 month (Investigated? ResuHs?) Bedridden: < 50% 0 Oral hairy leukoplakia or oropharyngeal 
of the day during 0 Candidiasis 
0 Vulvovaginal candidiasis> 1 month the last month 
0 Pulmonary tuberculosis 
0 Severe bacterial infections 
4 0 HIV wasting syndrome (weight loss plus chronic diarrhoea Andlor scale 4 
AIDS- or fever, what was excluded, and when?) Bedridden: > 50% 
defining 0 HIV encephalopathy (diagnosis by exclusion) of the day during 
conditions 0 Malignancies (Lymphoma or Kaposi's sarcoma) the last month 
Opportunistic infections: 
0 Extrapulmonary tuberculosis 
0 Candidiasis of the oesophagus or lower respiratory tract 
0 Pneumocystis carinii pneumonia 
0 Herpes simplex (mucocutaneous> 1 month or visceral) 
(date & lab result) 
0 Diarrhoea> 1 month due to crypto- or iso-sporiasis 
0 Extrapulmonary cryptococcosis 
0 Non-typhoid salmonella bacteraemia 
0 Cerebral toxoplasmosis 
0 CMV disease outside the reticulo-endothelial system 
0 Disseminated non-tuberculous mycobacteria 
0 Progressive multifocalleukoencephalopathy 
0 Disseminated endemic mycosis 
Table 5: WHO Staging System for HIV Infection and Disease. 
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2.3.8.3 Distinctive Features of Palliative Care in AIDS 
AIDS has similarities with cancer in that it is probably, but not necessarily a terminal disease. In 
both. rapid therapeutic advances are being made. 
Differences between AIDS Palliative Care and Traditional Palliative Care 41. 
• AIDS affects a younger age group in general. 
• Multisystem disorders are more common and more than one disease process may be 
occurring, a process called "parallel tracking" and "masking". Treatment of the concurrent 
infections may result in more effective pain relief than general analgesic measures alone. 
• Disease patterns are more variable and caregivers must be aware of a range of new 
presentations of old diseases, e.g. tuberculosis. 
• A more variable disease pattern which blurs the distinctions between cure and palliation 
relatively earlier in AIDS than in cancer and a careful balance between acute treatment and 
attempts to control chronic symptoms and conditions has to be maintained. 
• A more unpredictable terminal phase, with curable components within a progressive and 
fatal syndrome, resulting in complex decisions about treatment goals. Palliative services 
need to work closely together with acute sector to manage reversible components of 
illness. In practice the cooperation is not happening on a general basis. 
• Higher incidence of psychosocial problems. 
• Associated lifestyle issues and stigmata, which results in reluctance to be identified with the 
hospice Integrated Community-based Home Care service. 
2.3.9 Other differences between AIDS and cancer patients at Sl Francis 
Hospice 
Although the same referral form is used, the situation of referral of the cancer patients differs from 
that of AIDS patients to St. Francis hospice. Cancer patients are referred from a tertiary (or 
secondary) level to hospice care, which could be categorized as primary care. Cancer patients have 
all been managed and investigated by an oncologist and disease modifying treatment and options 
have been fully explored within the relevant health system and economic restraints of a tertiary 
institution. The referral usually includes an outline of treatment to date as well as recommendations 
for further management. 
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2.3.8.3 Distinctive Features of PalliatIve Care in AIDS 
AIDS has similarities with cancer in that it is probably, but not necessarily a terminal disease. In 
both, rapid therapeutic advances are being made. 
Differences between AIDS Palliative Care and Traditional Palliative Care41 . 
• AIDS affects a younger age group In general. 
Multisystem disorders are more common and more than one disease process may be 
occurring, a process called "parallel tracking" and "masking". Treatment of the concurrent 
infections may result in more effective pain relief than general analgesic measures alone. 
• Disease pattems are more variable and caregivers must be aware of a range of new 
presentations of old diseases, e.g. tuberculosis. 
A more variable disease pattern which blurs the distinctions between cure and palliation 
relatively eartier in AIDS than in cancer and a careful balance between acute treatment and 
attempts to control chronic symptoms and conditions has to be maintained. 
• A more unpredictable terminal phase, with curable components within a progressive and 
fatal syndrome, resulting in complex decisions about treatment goals. Palliatiw services 
need to work closely together with acute sector to manage reversible components of illness. 
In practice the cooperation is not happening on a general basis. 
Higher incidence of psychosocial problems. 
• AssOciated lifestyle issues and stigmata, which results in reluctance to be identified with the 
hospice Integrated Community-based Horne Care service. 
2.3.9 Other differences between AIDS and cancer patients at St. Francis 
Hospice 
Although the same referral form is used, the situation of referral of the cancer patients differs from 
that of AIDS patients to St. Francis hospice. Cancer patients are referred from a tertiary (or 
secondary) level to hospice care, which could be categorized as primary care. Cancer patients have 
all been managed and investigated by an oncologist and disease modifying treatment and options 
have been fully explored within the relevant health system and economic res~ints of a tertiary 
35 
evidence of immune suppression when evaluating patients for inclusion into hospice care. A trial 
use was proposed. The idea was neither tested nor implemented at St. Francis Hospice. 
At present any patient that tests HIV-positive and is referred by a general practitioner is accepted 
and cared for by care workers and home-care sisters at St. Francis Hospice. With limited medical 
monitoring, reversible opportunistic infections may not be recognized early. On occasions patients 
referred for terminal care are diagnosed and treated for opportunistic infections such as pulmonary 
TB in the in-patient unit, then discharged home with the prospect of living another few months or 
years. Theoretically, and in selected cases in practice, a patient could die in St. Francis Hospice 
being HIV-positive, although no WHO stage 4 defined condition was present. 
2.3.9.1.3 Clinical state and function of the patient. 
Neither the clinical state nor the function (e.g. Karnofsky performance status) of the patient is 
evaluated upon intake to St. Francis Hospice's Integrated Community-based Home Care Program. 
Each element on its own does not contribute enough evidence for "allowing" the patient to die. It is 
the combination of factors that increases survival prediction. 
2.3.10 Prevalence of pain in people with AIDS 
Pain in individuals with HIV infection or AIDS is highly prevalent, diverse and varied in syndromal 
presentation, associated with significant psychological and functional morbidity. Pain of mixed 
etiology is common. 4,8,41,47,78. The most common sites for pain are the head, eye, mouth, 
epigastrium, abdomen and joints. Neuropathic pain presents special problems. Bone pain is very 
unusual unless associated with malignancy. 
Reported prevalence of pain in HIV patients varies between 30% and 90%.4,8,43,41.41, ... Breitbart et 
al 19964,8 reports that the presence and intensity of pain are associated with more advanced HIV 
disease . 
• In South Africa during the time of the study, anti-retrovlral medication was not available In the public sector. It was 
available in the private sector. 
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2.3.11 Under-treabnent of pain 
The literature records widespread under-treatment of pain in AIDS patients.4,1G,4Us.47./IS. 
Breitbart, et al 1996' report that less than 8% of ambulatory AIDS patients who reported ·severe" 
pain, were prescribed oplolds. Nearly 85% of patients were classified as receiving inadequate 
analgesia (n= 438 ambulatory patients). 
Larue, et al 1997" showed that 62% patients reported pain due to HIV disease severe enough to 
decrease their quality of life and that over half of them did not receive any analgesic treatment (n= 
315, ambulatory care clinics, day hospitals and inpatients). 
It is not the aim of this study to determine the reporting of pain or to assess the severity of pain. 
This study documents opioid administration (types and dosages) in terminally III AIDS and cancer 
patients and uses the comparison between the two groups to arrive at conclusions about treatment 
of pain as a symptom. From the treatment outcomes pain recognition Is determined. 
2.3.12 Impact of pain on quality of life 
In patients with HIV disease, pain has a profound negative Impact on physical and psychological 
functioning, as well as overall quality of life."··s,,, In a study of the impact of pain on psychological 
functioning and quality of life in ambulatory AIDS patients," Singer found that HIV-infected patients 
with pain were more functionally impaired. Functional Interference correlated highly with levels of 
pain intensity and depression. 
Larue and colleagues" reported that HIV-infected patients with pain Intensities greater than 5 (on a 
0-10 numeric rating scale) reported significantly poorer quality of life during the week preceding the 
survey than patients without pain. Pain intensity had an independent negative impact on HIV 
patients' quality of life, even after adjustment for treatment setting, stage of disease, fatigue, 
sadness, and depression. Psychological variables, such as the amount of control people believe 
they have over pain, emotional associations and memories of pain, fears of death, depreSSion, 
anxiety, and hopelessness, contribute to the experience of pain in people with AIDS and can 
increase suffering. 
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Rosenfeld and colleagues" found that pain had an adverse effect on a broad range of psychosocial 
functioning. Pain also has an independent, adverse impact on psychological distress, depression 
and quality of life, regardless of number or quality of social supports or potential buffers. 
2.3.13 Barriers to managing pain in terminal AIDS patients 
Barriers to managing pain in terminally ill AIDS patients are related to the patient, the cliniCian and 
social and economic factors. 
2.3.13.1 Patient 
• Reluctance to report pain 
• Limited expectation regarding pain relief 
• Fear of addiction andl or tolerance 
• Fear of side-effects such as constipation, confUSion, nausea 
• Reluctance to take more medication (overwhelmed by quantity of tablets and injections) 
• Fear that pain be indicative of greater pathology and disease progression 
• Fear of being seen as a ·problematic· patient 
2.3.13.2 Clinician 
• Attention on incurable conditions or opportunistic infections rather than comfort or quality of 
life 
• Focus on social, emotional and spiritual issues and their role in the suffering 
• Reluctance to prescribe opioids 
• Lack of knowledge about pain management 
• Lack of access to pain management experts 
• Concern about addiction or misuse of opioids 
• Concern that opioids will affect the immune system 
• Time constraints 
• Fragmented care within the public health system (patients may see a variety of doctors) 
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2.3.13.3 Soclo-economic 
• Restrictive regulation of controlled substances 
• Access to care, especially in rural areas. 
• Costs (financial) 
2.4 Summary of central concepts 
Good palliative care is essentially to relieving suffering. Pain is one of the most common symptoms 
requiring control in incurable diseases. The relationship between pain and suffering is multifactorial 
and complex. Pain influences other factors that contribute to suffering as much, if not more, than 
they influence pain. HIVIAIDS is no exception: the prevalence of pain and pain syndromes in AIDS 
is well documented in the literature, as is the pervasive under-treatment of pain in AIDS patients. 
Severe pain usually requires strong opioid analgesia. Concerns about hastening death by using 
strong opioids according to normal guidelines are well documented as well as refuted in the 
literature. Inappropriate administration of strong opioids however, may hasten death by contributing 
to respiratory or other problems already present. 
This study determines how opioids were used during the last 6 days of life of patients dying in St 
Francis Hospice. 
The objective evidence of opioid-use was used as a measure to evaluate the 2 opposing 
perceptions within the encompassing framework of pain management. 
The management of pain is one facet of symptom-control. Symptom-control is one domain of 
several others that as a whole comprises patient and family (holistic) care. Pain influences the other 
domains negatively when present and uncontrolled. 
The process of providing care becomes meaningless if the symptoms (and reversible underlying 
causes) are not timeously recognized and assessed. 
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Chapter 3 Ethics 
Permission from St. Francis Hospice to peruse their records of deceased patients for a certain time 
period was obtained. Computerized data were kept secure and pseudo-anonymised. Names were 
stored in one file and connected to a research number. The data were analysed without identifying 
individual patients. 
• Autonomy: Protection of persons with impairment or diminished autonomy occurs in the 
sense that the community of dying patients, especially those dying from HIVIAIDS are 
vulnerable. 
• Beneficence: Although the patients in the study are deceased, benefits will pass on to the 
section of the dying community that will journey through St. Francis Hospice. 
• Justice: benefits of research will be available to populations being studied indirectly by 
making the results available to the management of St. Francis Hospice. 
Treating HIV-positive patients in a country with limited resources, inadequate infra-structure and a 
Significant level of illiteracy leads to many ethical dilemmas as well as practical stumbling blocks. 
Ethical issues are involved in virtually every clinical decision relating to HIV-positive patients. 
There are different theoretical frameworks72 available to approach ethical decision-making in 
medicine. From the Hippocratic traditional approach, an approach known as Principlism evolved. 
The four cardinal principles32 to apply when facing decisions are: 
• do good (beneficence) 
• do no harm (non-maleficence) 
• respect for patient autonomy 
• justice (equitable allocation of available health resources) 
What is necessarily the best for society as a whole and seems just, namely restriction of 
antiretroviral treatment as a trade off for other health care expenses, may be unjust for the 
individual patient. HIV patients in SA today almost have a duty to die in order to relieve SOCiety of 
undue economical burdens. The dependence on government decisions about availability of 
resources leaves the patients and their carers with very little autonomy as the people suffering from 
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Dlffer .... t Cu~U!es lIa~e d,lterent values and Ihl$ .ffects I'IOw l!ley pnorouze ethical prl~es 
CulluleS can be dlv>Cled 1110 2 groups itCCord lnglO the roles tlla1 cu~uraJ conl"" plays ,n peoples 
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Western cullUie Wllere palhallve care orig.nated is a low come~1 cullure The Xnosa and other 
lII(I,ger'IOUS cu~ures '" South AfrK:a are h<gh conte~t cultures, Ih ls set of odeals is of len refelled 10 as 
Western people tlOkJ onto an antemal locus of control, and planmng for end·ol·Ue folows tht$ 
srs:ern that IS based OIl personal chotceti F<x Low Context cU!lUres an ellllCCll approach that 
values the person (Pe<SOMI,sml.s Slfong\y advocated on rectlnt limes Personalism asserts thaI i1 oS 
the structure ollhe person thai defllleS lhe conlent of our m<xal dUl les 'Persona est affirmanoa 
propter se ip5<lm el propter d'IF"tatern suam (the pe<!j,Of1 shaff be alformed because of her-lhlll1self 
and because of her/h,s d'IJIU'Y I 
Ha.. well INS r~.s .110 a cullure where group onlel'esl {ubuntu) haS h,gher va lue than ind ividua l 
"'teresl 1$ questtonabie A Ubbtanan approach may be more aliraCtIVe m e H~h Comel(! cullure 
Ublilaroanl$m consMiers whetl>er an acl produces Ille grealest bene!ot of good lor th e greatetl 
number of ~"" The result5 of "" at;1 are ...mal counl, nol Ihe act ttse ll or the intentions 
LmllallOl'lS or Ihos approaetl are thai ""Ih our limlled ~nowredge, we seKlom foresee all lIle 
consequences of our aClIon$ 
" 
-"C"'h"'a.!:p-"te:.:r_4'----Hy path es i s 
4.1 Informal observation and speculation 
AI St. FrilnCf$ HOSPIce two ,ncQmpa\lll!e pojW::IE'S on the use 01 ,trong ODlOlds '" DeWIe WIll> AIDS 
were advocated oy IWe ddlMenl groupi on It'll! bal .. of 00P0I<1e MIl 01 opoIllOllS about the relatrve 
IIT1po<1anee al lndlCaUons for alld .. de-effect. of, oPlOtds 
• Death IllIallened In lome AlDS paltelllS I)y the uu 01 mOfllhone 
• Some AIDS patoent. doe wothout adequalll ilJIiIIge$Ia (Ofobebly because pain " not 
recognized) 
Because nMlle, ~mo had evo;lenee lO.\ItIPOIt their OI)lI'lIon, me present Itudy was pe rformed on 
order to produce objecl/Ve data lhat would test these two Iheor,et 
HYPOTHESIS 1 
11 ~ were adm,m'lefad 111 such a waV lllat they hasten death D8~'1'I1 recordl would ,how 
Dosages out of !he normal range close to !he orne 01 death &11<1 nursIng note. would (e!)Or1 ehangel 
,n conditions such ilS JIIn' l)OOIlt pupol, slowing respu'illIDn rate, menUlt clOlld l1lg and IOmnolenee 
Conc:orrutal1l admlfllStrallOn of sedallVeS could alao be responsible lor (or aggravate) theM 119"1 
HYPOTHESIS 2 
If AIDS pauents wefll 10 doe Wlthout adeQuate analgesia, their record' woold IhtlW thal they_re 
d'5uened when dying analgesia woukl nol be uH'd or wol.lld be started shortly lleIore de;ll\h anll 
analges.a would be used ,n lower doses 
There 1$ genera! consensus on starM.lards of pain management,n te rm'natty III cancer pallen!S wI"O 
!herllofe klfm an obviOUS controi \t'oup fo< !h:s srudy 
4.2 Substantive and statistical hypothesis 
The IoIlow.ng SUO&/.an!lYe hypo!h""S w~~ formed, Group A (AIDS patients) w~1 a,lf", (ex~ or fan 
shaft) of lI'ouP 8 !cancer pallt!nts) wllh respecllo Y (morphme admlmslfilhoo) 
Data lor tesll"'Ii (analys is and Interp rel<lbOn ) w,lIlocus on mo<phine adm l n l ~t ra!.,n 
Can&lderallOn of1he above 2. hypotheses gave nse to the foflowlng se1 of quest"'"s ccmpanng the 
g'oup of AIDS pat'ems with the group of patients with cancer 
To now miny palients In each group was mC)l'pI1,ne adm,mstered for each of the 5 da\'1l 
precedong dea1h? 
2 What was lhl aVlrage dosage of mom"'ne administered to each ~oup far each 01 the 5 
days p,eeed..,g death? 
3 Wl rl fher, d ifferences 'n IhI numbers of patoents betng admm<Stered morpl\lIle over 
d,lferent calendar yea ... oI!hI study for \he two groups? 
4 To how many pa~en!s in each group was II eambm.a1JOI'I of sedawes and opod 
adm'ms:ereej? 
5 What were lhe md lYoduat'nd il\teril9' do5ages of sedalrVe adm,ms:ered 10 each glOl.lp? 
Frcm lIle cllnlc.l notes (nurslng.nd mld!cill) 
6 Was the Iype of death (f! II ~mfu1 Vf!r1UI peaeeful ) dlffer,nt fOl' lilt! two groups? 
7 Old symptoms lutl! as fepofUng of pain . IIr$pI'lag" , shortness 01 bfealh . as repor'led on 
'dml51'on, d!fer II! !he IWO Ilfoupl? 
" 
Chapter 5 Methods 
5.1 Study design 
Ths was a relrospectrve reVIew of chni<;al records of two paral"' l groups of patrents to detefmtne 
whether there were any signoflcant d ifferences in practices of Slrong opoold adm,nislratlon between 
oncology and AIDS patients 
D,sadvamages of a prospect""" study In th,s selling 'Ir" thalli could influence practices in ma'llh",e 
adm,nlslraloon and Ihe small number of AIDS admiSSIonS per ye<l f W<)uid fe$Un in an d iffICult 
compromIse between st rength of conc lUSIons (whICh wou ld require an ImpractIcally long study) and 
fe<lsob,ll!}/ (whICh reqUlfes the data collection 10 be completed With,,, a year) 
5.2 Issues of measurement 
5.2.1 Variables 
How can one compare oproid adm,nlstratKln between the lwo 9!OuPS? Th iS WI U be determIned by 
how morph,ne adm.n'snatton tS eIIalvaled Rev'"w of the medictne chafts resulted ,n 24-hourly 
summanes of eqUivalent morphme dosages f01" £; consecutive days preceding death 
Do AIDS pat;ents rece!VO~ OplOtdS lor a shorter ~me? If a slgn lfiean, number of AJDS patients 
'ecei~ed oplOlds 10' ~ss thll n the last B days 01 hIe, It can be measured and compared 
The above measures do not gLve an odea 01 the cause 01 death The patients' notes Were read aOd 
an OpiOiOO formed whether ,he death could have been opioid related [sudden or une ~pected 
deaths) Together WIth 1M op:old dosage escillatlQn one could posSibly conclude wnether the opooid 
perhaps cootribuled to the death or If death was due 10 disease processes 
An entry klr type of deillh and oplOid dosages.s thereto<e necessary 
DISCUSSions were he ld Wlln staff and documented 
Differences In dosag" 8nd dO:;ilg" escalallOll These were ca lculated and means determined Th iS 
serves two purposes, a) 10 contrloule \0 the conclUSion about cause-ol-death of patients who were 
Inalated OIl mCM'phln'" therapy dUring the 5 days before day 01 ~alh and b j 10 establ ish comparil!Ne 
clo$age ligures between !he two groups 
The indication for Of)/dd use may differ IndICations are usually P3ln, dyspnoea Of cough Are \he 
CiI1egones of ,ndlcatoonS sImilar for AtDS and cancer pat ients? I trled 10 form an opmlOll iIbout 
iOOICil!tQn lor optood use from revlewmg!he medIcal notes In each file As Indkations for oplOid use 
were seldom di reCllr rlOIed, the idea proved dlfflcu~ to put Into pul Into practICe and I /I.ldged It ilS 
not contribut ing to resu lts 
Role 01 Pain and discomlOll scales in evi!!uatoon to establIsh comparable standilrds These are nol 
used at SI Fraoc,s HOSpICe (apart from the symptom Ifst on aclmisSlOO) The mertt usefulness and 
inaeased workload versus t>enelOts to Ihe patients ware d,scussed In team meelll'l9s A de<:,sion 
was made against change 01 the present s;luaUon 
Sedat/Oll, II administered inappropriately in conjunction with OP'OtdS, couk! haslen ~ath Database 
1",,1d entnes to rKOrd sedatiVes admin,stered were provided lor AJthough halope~ Is classified 
as a classica l neuroleptoc . the main IndlcaHan for use In SI. Fraoo s Hasp~ IS lor nausea The 
mtent 01 ~s use as::I tranquilizer! sed .. t ... e IS d,fficu lt to evaluate 
Team meetIngs (~osplCe team managing cur P3l1ents) were held and Input from the team was 
evatuated for luoher (;[Itena to determine dIfferences In pallems al treatment between AIDS and 
cancer pat,ents Meet'fl9s were usellJll{)( lhe study as welt as evaluation anti dISCussion of present 
pracliees 
When lhe patients spenl a portion of (helr lasl 6 days outside af SI. FrancIS Hosp;c.e, no cletalled 
recCM'ds 01 OPlOltI use is available An assumption was made that Piltients used the apfojds al nome 
as prescr ibed Na rescue dosages, omissions or boosts Irom Ihe syrmge-tlril'er can be taken into 
accounl as II was not noted aoo the,elare 001 known II a relatively large number spen1 less Ihan 6 
days 10 me in-paMnt unit, the quality of !he oplOid dosage tlata may be alfected length of stay was 
noted and evalualed wllh lh,s., mind 
5.2.2 Selection and exclusion c riteria for AIOS patients 
Selection cnterion 
Panents dymg in the in·pallent Unit wrth AIDS or complicat"ms relate<! 10 AIDS (WHO stage 
4) between August 1998 and December 2001 
ExduslOf1 cnterOl 
Co-occurrence of AIDS and cancer death unrelated \0 AIDS; records not availab le. paM"t 
not evaluated by SI. FranCiS Hos!"ce doctors 
lnot-at co llecuon of files from Jan 2000 to December 2001 tdentlfied 27 AIDS·re late<! deaths 
iICC~dln9 to the comblnabon of the Admission- and Undertaker· books, Of the fi les accessed ' rom 
the 27, 7 were e~cl\lded The reasons were- 1 doed 01 cancer of oeSOpha9us, t of lymphoma. 2 had 
KaPOSI sarcoma, 2 f iles were not fOund, I died Irom a gunshot wound With no prevIOus evidence 01 
Immune defit:lency (high wntte cell counts Indicating adequate Immune response) 
The el im,na1ion precess rnu lted ~ 20 I lles bein9 accepled lor da1a ,nput 
I decided to Widen the perIOd to August 1998 when the sequential records 01 dea1hs In the 
Undertal<er book was commenced A lurther 12 pa1len!s were identified for which 3 did not meet 
selection crdena 2 had lymphoma, 1 had cancer of mouth Th iS brou9ht the lotal 01 AIDS pat tents 
who died 111 the ~·pa1l ent unit from advanced AIDS to 29 
Data lrom the f il es selected for the pilot study were Included due to small numbers 
Irv.livtduai case d iscussi!:m$ With the other medical members of the learn were held to eIIaruate In 
retrospect the vaDdlly for Inc lud.ng or excludIng patoents In lhe stud1 
5.2.3 Sample size 
Standard power calc~'anons were not performed before the study because Ihere _re InsuffICient 
data For descriptive studies de Vos recommends a sample size of about 80% 01 the popy latlon 
when th,s ie h .. tw .. an 20-30" 
5.2.4 Measurement too ls and data collect ion 
Each step reqUIred thought about thi! ~ I nd 01 evfdence It would proolJCe to enable the seJlKltJOf1 01 
1hII !nOS1 oIJ!eelrvf! Of unboased mBlhod 01 collecbon Whme measunng inslrumenls had 10 be 
appked 8 liIeraiure search comboned WIth the requlremenlS lor the study Will uSed to dec,de on 
appropoale Ilems 10 be llld.lded 
1 Dose Morphine equIValents wen! c:aiculilled lorlhe 5 days (6 J 24 hour per,odSI preo:ed,ng 
death These c:aleulalldlls formed lIIe bas.s upon whodl compariSons 01 dosage. dosage 
escalatoon and Ierlgltl 01 opo:ltd lreatmenl were dete'mllB<l 
a For oral 1llU1e5. rOUhlle admon,SIIiIlIOIl!l Irom Ihe drug CMart (4 hourlV) ami prn 
admm~lIations (bme 01 aOm,n,s\(anon IS chartedl was enlflred Dosages were 
correlaled WJIh nurstr151 noIes as lI<SO,tIonal aclm ... ,strallona II)CI omlSS'onS are noted 
tIIere as wei 
b. For synnge-dnver routes. the dOS81le5 were ealo:\llataO II In hourty rate lor the lime 
penod the lyIIf>ge.(lnver was runmng Caleullhon d,JI.ea lor the tiftC d'~er end III-
"'bnO as abaJt 0 5m1 rema,ns In tI"Ie needle II)CI tul);ong Ind thus led...ee1 the lime 
over wtllch Ihe 41wer can run BoosIS ele Charted end were added 10 Ihe hour ft 
occurred ,n In the evenllhalIn. t ..... 1*io4 (""Gong booSIS) does nor cOII"ei:ate 
WIItllhe prescription. \he Oosage 01 morpfllne would be dIVided through !he IlIIIllbef 
01 hours III. s~""nve< fIn The SC dO~ .... r. eonve1e<l to oral IIqUlV8ienl 
Gosages by mulhplylng by 2" 
2 Time was ehaned hOurly alowong haft an hOUf on each side As Cl'larts mey reI\ecI. nail· 
hourly IamBS, X 30 was Charted under X.OO end not (X·' ) 00 10 IT\a!f1taln conSIstency 
The houl1y dosages 01 OpIOOd were emered on an EJ<eeI spreadsneel. 24 hour summanB5 
ca lculated and entered on the Aee81IS ma,n dal3lHl$8 desogn«:llor the study 
3 T YJ>IIend lOuIe 01 Strong opoood admfll!lBfed were recorded 
4 I!ldreat.ons lor opiClid use were elasslfled as PIIi'n, eough, dyspnoe • • eombo031lOn' 
5 Concom,tant Sedarrve admlo ahatlon dU"r\Q the IeSl t2 hours The comblnalJon 01 sedawes 
and opiolds cou ld ~av a role In naSlenong d88th For thll I88SOI1 eoneom'l3rl1 seoawe 
adminiltl8bon was documented end allillyzecl Type 01 sedative iIIld dosage IIJV811 duflr'l\J 
the last 2~ hours W81 entered Two cauIgor,iIlS were odlll\t,fied Senzod1iWlP'neI were 
~1c1,lJ31ed 10 m,da2:Qlam eQurvalent" The olher 9rooP compnsed nevtoleplO::S The onIv 
Ile!IloiepIlC drug used rn the study grovps was ha10pendal 
6 Type or dNlt> was determ,n/l<J from C'nlCal records and cIaSS,f,ed as peaoefu~ pail'lfuI, 
resUell/ag ,tated other, unknown 
7 Speed of death was ctass,fled liS gradual Of svdden Mosl pat<e<1ts grad...aly de:enora:f! 
unt ,1 the1 dte A $lJddiln death, not expla!lled tJy other symptoms Of onodents could pOInt to 
pelSslble misuse 01 ooloids 
The fotlQwln!il two pPII1lS (6 ilfId 9) adOrest lssues tIIa! line d<ffieU1t 10 measure acCI.Iralely If'[ a 
retrospective study The Quest,ons attempt to e$l,mate If unrepofled pam ~ ple$C1'II tn AIOS 
pallenls 
6 On adm,non pro/)jemlllC symPtoms are rou!;~ llOIed on II SIiIrrdard symptom bst 
glade(! ;JCCoro 'ng to subjectrve paIlenl evalua!or:rn elthe Imp(Mtan<:e 01 the probJem Five 
rtems wele InCluded If'[ lite resean:h da:abase namely pa,n, dysJIIIag.a d)'1pl'lOea cough 
lind confuson Pre.enee of symPtoms WH entered on tile .omlSlIO/I date, and one would 
expect that tile symplom would "-ve refevane. dU1nv lite ltll 6 days 01 We It cornnbuled 
10 fOfmrng a genef. oouron 01 whellier symptoms that could have been treated wltll 
opklids were Pfesent 
9 AlOS IS • no<l-spI!CI1ac: dragnosrs When pattems are referred, the accompanying 
documentat,on seldom con!lIIns ""ormatron about speerfic opportUlllltlC ,nfections present 
11 would h .. ye been u~t 10 note other diagrlOStlC ent,bes re lated to AIDS, e 9 diarrhoea, 
oesophagn,s, perIpheral neuropa'.tJy, menlllglt.s and other. The combinat ion 01 
Qe$ophag;hs, pan nce reeOfded on the S'/mplom chltrl, and not re<:e'y'ng opioodl on 
adm,ss.on, may be an InchcallOll Ih.a! unOef·reporUt1g or pain may ~ay a role In non-u~ of 
OQronSs Thl$ Idea could n01 be develOped In!O II measure of the quailly-of-(;ilrf! as the 
records dtd not r:onralf'[ enoogh diagl>OSoc mImmation m \he malO/I!Y of AIDS p1I!oents 
A queshOl> \hat lab ..... ~ the scope of !his stud1 IS How f1/fOC!lveJy do we u~e opKllds ~ 11M 
paII/aIlYe eIIre 01 p«JJl1fi dy!rIg from AIDS? ThIS Could be t>est aCldresse<! by II prO$pl!dLIIe n.rdy 
" 
5.2.5 Type of death 
Type of death was determ,ned from a comtllnat'O!'l ~ clinICal and OOt,"'g tI(ltes Calegories di!1,tIIKJ 
were peilCefol paln'ul. test'en. wet chest 4. d)'$~noea 
Interpretat!Ol1 reqUIted !WIl1e Judgement In Inlerpretatlon al shown In th' exampJe below where the 
~abent had a panIC attack. moaned loudly and th en "died peacelu ll ( The da~1 befor. were illso 
marked with anxlf!ty 
DATF DOCTORS' OtH>I;.R!i &. "'URSI ..... G ",O rES Sf< 
;lI\ ..... <.:I ~m.hA.. .. -.2 \"""'" . _J. ..J.J ~~ H': _ -C:"'!'-' A. . 
• '-»- '-'b 0·... ~' ''a''\\'::)-,i 11. .. --'-\., I 
~ <:; :~. kid i<l44 ""-L< Ci<W' taL f. 
,111!P!'t:Aiu?.fA. ~. .21 .+1 -rtJ f lUP '"'~ 
Flgu,. S, EX I'ICI'",m " .... ing notn. 
5.3 Data collection 
5.3.1 Identi fy sources and gain access 
The Inl 51e0 WM I:) Idern ty HIV.pOIItrie pllbetllJ. dy.ng .,!he Ifl·pabent OM 01 SI FranCis HOSQICe 
who CO\IkI be dMsdoed.' In., ildvanceo stage of AlDS (WHO slage4) 
NO eomputerQ:e<! r..:<l,d'lhaI could Oer\l,fy these QiJloenIl wera available An -AdmISSIOflS Bool<,- IS 
kepi where a patl ...... name dal' 01' ildmlnoon 10 Ihe In-pall!!flt uM and aoagnoslS'~ wfllten. USing 
tltll I compolaa a lisl of the adml55101"1S of pave".. With AIDS to the Irl--panant \.1 ... 1 from August 1998 
10 o.cember 2001 NO! every P'!lenl Idm'lIed 10 the In_pallent Unit d.e. there An unknown 
pe1~ of !he patient' are d>SCha'ged home To identify AIDS pa~en!& who d.oo In the In-pallent 
un~ the 'Underlake~ Book- was used ThIS reg stitt was _tmeo In AugU$\ 1998 and InclU<.les the 
date of duth but nol the cause F,om llll ~I$I Itst 01 AlDS·Dl111e11t admlSi ionl. a ~mallflr li st of 
AIDS-patJentl who c'~ lf1 the ,n.pallent UOI! was selected 
., 
The IoIders were oblaltled and da'.a captUrill<l and eIIalua!ed A few pa~enl5 did no1 metl! the 
seil!!CtJOn cnterIa (see below for detalls) and!he!r data were di5carded 
The control group 01 callCef pa!!er115 W3$ Cleated I.IWIg the I ,nal 11$1 or AIDS dealhs and II\e 
Under'.akers SOOlt to Identify for each AIDS death rhe 11'$1 sl,/!)Seq\lenr p31,enr who ched I.om 
cancer and me! the selectIOn efl:ena ( ~DeIow lor detalls) 
5.3.2 Field notes 
Notes ~re kept or the pfogress pfoblems ,nd qr.teslrons thai arose.s \tie r~,rell proceeded 
From these nOies. leam meebngs group dOK\lslIOnS and peer dlSCUUlOtIwete 11'III13ie<2 
5.3.3 O,t, e,plure 
Three data tatlles were Cfea\ed in ,n k;cess dala!)ase Tile daLli wel e e'ptured by m)/$ell It 
cons,ste<! of a m1xlu.e of f\\Jmerle arod le~tual clata NumBrrc data such as morphine l1S3Qe and 
d""9es lends itself to a atnx:!ureo and relall~1!Iy slm~e caplllre metnod 
Te. lua l categolles we'e developed 10 ,nctude t!'Pl! 01 death speed of death. sedatoon leqUJred 
Proo l'ion wu made lor notes to elaborate or elicit par1lCUiar aspects of Impanance Of relevance 
Nursing notes were evalu'ted to reach it COr>CiuslOn about spiled and type 01 death 
5.3.3.1 Patient details 
Tile Iksl selectIOn effor r involve<! obtaining genera l patient deta ils such as hospice lolder number. 
name. &ge, gender. elnnO(; group SOCIO-e<:onorrllC status (IndICated by pnvatery managed prio' to 
adml$SIOI1 or manag'lmenl by goVetlln'lentalstruClures suell as local cr.n.cs or a provJOCIa l OOsp.tal) 
Each pat""nt was aJocateo a reference number thaI pfov>ded anon~m lty for furlile! entnes Data 
was ente<ed from paper records 
5.3.3. 2 Core data 
The ~ table eont",ned the oata:he matn analys4s was tlased on Tile eore CIa:. rne!lJdeo 
Hospoce loIOer !hrrk to patienl ~klI'm;lt!O!l) 
Place of death, lope!her w~h date and tme of oeath 
• 
ROUle 01 8dl'l'llnrstrallOll This os requ'ed 10 Cllculr.e equl3nalg!'$C tiel., At Sl Franca 
HO$plCe we elicui:f!e !he 5Ubcu:3nI!OUS do$e a! 5O'to 01 the 01111 00stI "l1li The orlll 
equ,..~ 01 morl)lwle dosages ~ UMCI lh'ougllOUl the 1!UCty (SC OOItgef __ 
mU~JpIoed by 2 In 0f0er 10 be ~ ICIIl'Ie OQII~'" 
Ty;:.e 01 <!NIII was eategorl.!:ed as peaceful Dalnl\A restless . unknown. YOn'U\lng we( dlest 
and dys pnoea TI'IIS m~n s)'II1ptom was eIoeIted from the "",Hlg notes P_ dlSCUSHln., 
well III nul'$ll'lQ II'Iput Wi115 needed lor ~.1011" it lew C;35e5 
Speed 01 deal'! SWden or grad~ From re..:lorog tI1e nuI'SIng nates .., 0pII\I0n of SIJ8'd 01 
death was lormed One pal.enl doe!! ~ oil t.rge r.eurysm Ihill *" The bleed _ 
anhClpated and appIopnit!e paIhatJve me_ ""IIfII taKen 10 .etammoct_ ~ 
Sedatives used Yes No and type and cIosage III last 2~ /louIS 
5.3.3.3 Relevant supporting data 
A sJ'lTlplDm sheel .... th 33 Srmptom5 IS eom~ Iof eacn admossOOl'l by lhe ruM The lormlll 
lends ltSeW to eatI~ caplule From InOS, a m,rd rabll was Oes<gned II'ICOI'pcnt.ng ~ey aymjllolN 
relat!!od 10 Ihe stlldy lLOCI! as Ihe presence of paon, dylpnoea, eough l'Iause. and I'OITI"""" (lor wtlICl1 
I'IaIopendol'5 often acilT1ln" tered as a flrst·line drug) contul ion, r'l!i 
Il!l5UO:; Of,SUV.\TICIIS AlII ASSlSSIIPJfT$ . 
l. _'T I0OI 
, , , • CO IOIt u..L ,. ,M' 
•• ~ V ,. ~~ V . 
•• ..... s,u .. nON . , . , ........ 
•• . ~-,. PIUS 7 
•• lo;I~n .. ~ • ~~ . 
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•• _ ........... , , --
" 
5.3 .• Data quality assurance 
Once lhe data wele entered the lilbles were ~ua!ed foIlackl abs~ gI cIaIa. II'IeOI'I$l$leoe.es, 
ard cbvIous errors I also discussed undeaf Impo'f!ssoons w th coIeagues emCloyed" 51. Flanca 
Hospoce J'\ an aIlemlll Ie obtain objec:lM! In'armilllOll W,th!he IIflter .ng In lhe Excel Subset of 
morphJ'\e acsages lhe I!I1l11es In !he exisbIIg Access dalabase _t I~ed A I ..... sample 
folders were seJected and han6ed 10 a CO::eague IlDI related \0 St FrancIS HOS~ 10 complete 
printed data capture forms The goal 01 this requesl was 10 ... aI\I8It my OW!'I e\IrUt:;.aI jUdgment 11\ 
evafualJng the files The!wo sels were compared arid no Imporlanl d,orerltf\Ces were found 
5.3.5 Data analysis and synthesis 
The tables Wllft bnkltd in Access and the rl'le';ant ~1Ie"eS I\If1 
A li st 01 paloents who Wefe uSlI\g SlfOflg OIlJDIdS was H IIICt&d The IISI wn kfllpo<t&d 11'110 Excel A 
spreadsheet WIIS des'gned to eol&r motphll\e dOSH a(lm""srertd on all hourly bas 's Adjllfokfllenls 
were made to use Ihe oralllqu,,",alenl 01 subCutar'leOl.lS dD!i1lg81 (SC mull~,ed by 2) Worl<ong back 
Irom Ihe lime 01 death. Iht l'Iourty values 01 morph'r"III IKImilllSlral ion were summlrd in 24 ho\.Ir 
"' leNalllor 6 COIl5eCutlve dII~l. obtaining the dalty morph ine dosage 
The 24 hourly re,u lts were enlered Into the AcceSS database Qusry resulls were copted 10 Excel 
Graohs wele drawn Irom the query rHull, 
5.4 Pilot study 
A small .. mille 01 AIDS and cancer pallent. was obtasned to 
dllCover errors In the data caOlure deSIgn 
eYaluate lhe de.9"o ollne database lor mlllllpulalion 
• M'H' the proposed melllods foI anatyn'lg!he data outrome 
The type oC opOld adm,nl$tllf&d was s.grnlrClll'l11y d,lIereni foI cancer pal,ents A number were on 
OI,ll-slllSIC: , 'enranyl). bulll_OIwle or o"lOIds noIavailabie In the pt"O'I,ncoal hoSPlaf, . A dose look 
81 the geog"'oc data showed thaI II>e AIDS 9'DU9 conformed 10 the genetal popuIabon as far as 
SOCIO-&conomIC status (maJonty no! on rned"al a,d·) and racial grouping was concerned The 
cancer group shOWed B maJo<ity 01 Caucasians compared to the other ethnic groups A S'9nillcant 
percentage was on medica l Bid or was able to afford prIVate medication. 
LOOking at the ava.!able general staustics of SL Francis HOSPICe, It IS noticeable Ihal cancer 
paI>ents are main ly Irom the whole population group. The slight difference from the grand total 01 















To orcum~ent bias In the sWdy It was deCided that selectIOn cnteria ollhe cancer group ShOUld 
sl.pUlale somllar sOCIo-economlc baCkground 10 AIDS palients A simple way 10 achieve the newly 
!lelined selection crilena was to choose the fo~o'Mng death ' rom a Similar race group patient with a 
simila r medica l aldl non medical aod history 
5.5 Data capturing and data analysis 
The author designed the forms (In Access) and captured the data Microsofl Access was ~sed to 
summarize lhe data Graphs were drawn in Microsoft Excel 
5.6 Statistical analysis 
TeSTS lor STaTistica ll y Signif icant differences were ca lCJJlared IISIng Ihe standard funCbons pfO'Vlded 
MicrosoftXl Excel 2002 (Mlcroso't. Corporation, USA); Chi square test and t te$l and 
Stata 7 G. (Stata Corporation, 4905 La);eway Drive College StatIOn. Texas 77845, USA) 
FlSner exact test 
The I lest was used to compare means, the Chi sql.l3re test was use!110 compare PlOIlOIbOns 
5.7 Shortcomings and sources of error 
5.7.1 Access to data 
5.7.1.1 Inaccessible data 
Two hie:; lor AIDS patients could nOl be localed and lhelr records were omlned 
One tile 01 a consecullve deatn of cancer pal lenl5 (w~h same SOClo-economr<; sial us) couk;! nol be 
Iocaled The second coosecutlve dealn (With ~me soe>o-economr<; status) was lOerMied and 
selected 
5.7. 1.2 Incomplete records and mIssing data 
Not allinlormatlon requ>red lor stuoy pur"",se:; was available For e~ample seven symptom chans 
were absent or not completed from cancer patients fok;!en; 
For the AIDS patoenls. assoc,ated condiMns were no! alwa~ noted adeq""te ly A conlrlbuMg 
facto' seems to be that the referral form does not make prOVlSron for slICh detail 
5.7.2 Errors in using existing dCltCi collection instruments 
Although morphine dosages are compared across a Wide spectrum ot pabents blood levels are 
Influenced by several factors Factors that Innuanced the pharmacokinet.cs 01 oplOlds canrlOt be 
determined retrospe<;tovely from cllll.cal charts 
Palients are not w~rghed One woukJ expect d'fferent responses to 10 mg 01 morph,ne In a 32kg 
and a 70kg adult Tnere IS little InformaMn avaolable in the notes to form an Opinion about weight A 
percentage 01 b,as Cim t>e expected rowaros uMerwetgill patients compared to normal or 
overweight patients 
Absorption . metabolism (inc luding tolerance) and excretion cannot be determ,ned as gastro· 
Intestinal StaSIS, liver and kidney lunct.:!rJ fa ilure concomitant use of I",er enz~me-,nallC"'g drugs 
were not routinely n:)ted "These factors were exc luded from the study 
5.1.3 Errors in scale construction 
The measurement scales tor modi! 01 dll!a1h. speed of dealh have not been formally validated n 
tlYli W8!i beyond tl>t" scope oIlhe prtJteCt H!7oO"evet they are simple Intuf.rve and wOI.IId s/!em to 
haW! face valldrty 
5.1.4 Errors in data collection and documentation 
I coIe<:ted and doctJmemed the data myself The drawbidt frOm I ... " :hal I was flO! 'bW!ded"' I 
Wall <MiKe 01 the d1<'lIno$$ research ques~on and background of lhe study To Han t/1IltJetent d 
this pass,toIe boilS a colleague thaI WilS not connected to SI. Franc" HOSpICe. evaluated lOf eacrt 
grc>UP 10 folders selected b)' a third party no! invoIIIed wl\:h the IIudy My coIeagl.ll was 'bWK*j as 
to t~e !rOUp The dISCrepanCIes highlighted \tie dll!icultres on lemaumg unbiased I .,,~ to the Ide 
of cautIOn aod 101" e)'ample calegom:ed mort! ' peacelul deall\t· !hiOll ltIe non·hosprce eoOeitgUe A 
mee~n9 was sel up between mysell and another eotteawue from Sl FriOlletS HOSpote iOIId the hle5 
were re-evaluated for IWbjec~ !»as 01 rnput When dll'Ieuttres OCCUlred '" deo5ron mak"", tl'lly 
WIl,e discussed wltll members oIl11e team who were Involved Wt":h 11"11 specIfic patient 
I may also be preJu:ioced, being involved In oogol!"l!l debates WIlli $UlU over IIIe POlleY of "'"'9 
morphine In dYIng AIDS patients and adverse efleets or l)enel,tS II COllie! pOUIIlly have on the 
patoenlS 
The Hawthorne ellecl" may have been present as 1I\e Incidence 01 morpllone use 01 AIDS patients 
mcreased during the study perkld (lee Figure 10 on page 65) 
5.1.5 Errors in data-capturing 
The do.agE! Of the morphone was str.;ughlfQlWllrd and was double cl"lllcklld for err~ In entry 
sedill' .... admmlSlralon was 1\01 recorded lor th,s study In the same deta,1 as mo<phme II was 
19C01ded !or IhtI lint 24 hOurs Tnt reason ~ that 11 ~ ~nlr~ely th,t • ledallve atlml!l.lSlered more 
thitfl24 rIoufS before dea:n would contrlbu:e to ~ 
OjllOlld-l; uslld a1 I"lome w_ no1 Charled in lhe patient reeord Tile,. were no enlt..,1 pertaIning to 
comp~ance. rescue do$ages or om,tteO dosages For compa1tfOn. II was "sumed thai morph ine 
" 
was \I$ed as presenile<:!. wrtllool taking lI'IIO aocounl ormnoon or rescue doWges Thll number 01 
Slay.QaY$ was entered 10 rl!(l()r(l arx:vrnt~ lhe number of days !he dotferenl pahenls sperII on the ... 
pallenl un'" 
5.7.6 Errors in analysis and interpretation 
The use of onapproprlate sliIl'stcal procedures Is a poss'Dlilty AdvH;e and asSIstance w\!'I'e oblaJnell 
hom a $ta!l$llOM 
Chapter 6 Results and Analysis of Data 
6.1 Sample profiles 
Cause 01 death 
AIDS 
"~"" 29 " 
Age mean !morumum- m.tx,mumj 35 [21-60) S6 [21-89J 
Se~ rallo, F Pol 14 15 1910 
Health care luoomg StatelPowte ,., "" 
Ethrnc Q'OUP BlocluColout'eOlWMe ''''''' ''''''' 
T.ble I ; Pat, ... , cll.r.cleri'l iin 
Twenty nne patients WlIh Advlfle&d AIDS were denlll~ who doed In Ihe in·paloenll.l~ 01 51 
FrlnClS Hospoce balween AugUSI 1996 and o-be! 200 1 and met $e!eCbon elltenB From Iheu 
dNIh dlllH. 29 consecutIVe car>ee< p811f1n1a who O>ed WIth II smila. IOCiO-eo;onO'l1Ie baeli:g.oond 
wen! 1dtnI1"ed M COf'Itrob 
(01 e1Mltltl ana 
(_) fundll'lg o! lIe.tth cafe as PlIbIo:: II III stale patten!) Of prIVate (I e medICal aid pat,ent) 
6.2 Main findings of single factors 
6.2.1 Total number of patients on morphine 
6.2.1.1 F;ve days before their day of death 
0-' 
Patients on morphine 








Tobie 9, Numbo. 01 p. !i~n ts en merphin~ t hoc l05t six days 
P" 0 001. Fisher e.~Cl le~t 
The proportlO<1 of people re<:ewong morphine 5 days before dying from AIDS is sognlf>eantly dltfefenl 
Irom that an patltmts dying from c~ncer, p< 0 001 IFisher exacl test) 
The result contrasts sharply With both the compar ison group of cancel pat ients of whICh 69% 
recewe<l morphine f"a days belore death. and the hteralure on pa li lati.e care practICes elsewhere.. 
6.2.1.2 On the day of the ir death : 









29 p" 0 038 Fisher exact test 
hblO 10: Numba. of pal ien ts on morphino on tha day of their death 
On the day they died, 12 of the 29 A IDS patlerJts m the study (4t%) rece l.ad no opiOid Only 3 
(10%) of the 29 AIDS patients were USlfl{j morphme for more than 5 days before th~ died 
6.2.1.3 Increase in number of patients on morphine 
For 11105 palients tillS is an Increase in numbers of 470% from 5 days before their death. and for 
carn:er patients 25%. Desp Ie thiS large inCfease. the propowon of people With AlDS rece i. ,ng 
morphine on the day of then death,~ sl9niflean~y different from tMt in pat,ents dying Prom cancer, 
59% cf 86% 
13 caneer patienls (45%) received dosages higher thilll60 mgl24 hours 5 days belore toor death 
compared 10 I AIDS pil1iem (3%) (p < 0.001, Fisl\e( exact) Three 01 the 29 caneer patients (10%) 
received morphine lit dosages 01 more than 300 mg pI!f 24 hOi,JrS_ No AtDS pauents in this study 
received morphine at dosages higher than 300 mg pI!f day. 
The to/IowIng graphs show the dmerenl pattems 01 strong op;ate use accnrd,,".g to dos.i!lge In AtDS 
and cancer pa~ents al SI Francis hospice 
Figur. 1: 
AIDS patienl& on 
morphfM 
(n 0 17 or 29) 
Figure 8: 
e.neer p;tl.ntl o~ 
morphine 
(n 0 25 of 29 ) 
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The pictu.e of cancer patients on mOfphlne looks vaslly dltferent "om thal of AIDS patients. The 
morphine dosage ol lne 3 AIDS pabenls (10%) whO received morphine for 5 days or more before 
death, compa~ reasonably wetl 10 the morphIne dosages of cancer patients receNiI1g morphine 
for6dllya (or mo.,,) . 
" 
6.2.1.4 Number o( patients who died within 48 hours after starting 
morphine 
Opoood " 24 hcurs ~DS 
Morphine < 24 hours " 
Totat 






" of tne 29 A IDS patients (I.ed Wdtlill 481loufs or beong initiated on morphine (Number, Increased 
from 6 to 17 pahents r"'~g morpliotnlll Expressed as a pl'!l'eenrage of tile AlOS pa!~tS wno 
wete receiving morphll'\e (17 in IOtaIl. f calwialeS to 65% 
4 cancer patients (14':11.1 wele sta,1ed on fOOfptlofle dunog the last 48 hours QI Me 
6.2.1.5 Morphine dosages 
The maJCtfTlum dose fOf AIDS pabents who .!>tarteO morp/'kne du""glN! last two days 01 1,1111 was 50 
mil per 24 hours Ttl S IS "",,11m the normal tlleraplllu1.e ranglll 
f llerlll was 1>0 e xcess,veIy large InCreases In senal mo<ptl"l'" 005age noted In Mher cancer Of AtDS 
60 
6.2.2 Average number of days morphine was adminis tered 
The average number of days tnar AIDS patIents wer" g iw,n morph irJe was 1 e and for caflCer 
patoents 4 5 ( ma~Imum n=6) The a¥erage number of days Ihat cancer pabeJ1ts rece ived morph ine, 
15 on ly applicable 10 th,s SILKI~ and is nol reflect,ng the period before the last week 
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figure 9: Avcr.ogc number 01 day. mO'l'h ine w.s adminisle",d belore du,h [bars indica,e 9~% 
confidence inlorval'l 
P< 0 001 %, from I \est 
Tn .. IndICation for uS ing morphine In te rm,na lly ,g patients IS usually 10 palliate pa.n to ensure a 
relatively symptOm Iree death" .. W,th refractory s~mploms preva iiong, sedatoon ~ often used to 
adueYe control The next steps on the anal)'S,s exam,ne 
sedabon adm"'lSlered 
the kind of death th at occurred, and 
symptoms notll<:l on adm'SSlOn tn the two groupS 
6.2.3 SGd"tivG "dmlni,;t~"tion 
None of the p311ents In tM study rea!lvlng sedat ives wele sedated to a state of unconsciousness 
6.2.3.1 Types of sedatives administered 
TwO categone! of seda~ve used dunng ttle last 24 hours were identified. namely benzoclLazeplncs 
and neuroleptocs For e3sy coJnpaffson equlllalenl doS3ge5 were c31cu l3ted For tIl<l 
benzodl3zcpine groUD 3n equivalenl oral midazoiam dosage for tfle 24 tIou r perIOd was used 
H31opefldol W3S the only neuro lepltC admonlslemd dUI;ng tfle last 24 hours An patJems who 
mcelved Nliopefloo l were Qlven ~ Ily subcutaneous route lor nausea and vomiting No patient in tM IS 
study selection rece ived ha~ooenool fO( sedatIOn NeuroleptIC! were lherefore excluded from Ifle 
6.2.3.2 Incidence of sedative administration 
COmP3red Wllh c .. mcer patients SIgn ifiC3ntly mO(e Of the AIDS patients receIved sedatIves dlJrlng 
lhe" last 24 hOurs 12 of the 29 AIDS patients . 4 of the 29 caoocr pati!!nts p" 0038 (Fisher exaCl) 
6 .2.32.1 Number o f patients receIving sedatIves 







Tota l 29 29 0= 0.038 FISher exact \esl 
T. b le 12: Number of patients 10 Whom sedOllon wu Odm lnl5tered In Ihe 10 .. 1 24 hou ... 
6.2.3.3 Dosage of sedatives administered -------
Mld;uolam cmg per 24 hrJ AVerIIge Ma .. murn M .. ",.,um 
AIDS " 23. 7~ '" ---
Cancer " 
Table 13: Dosage of scda"ves of patients (mi fl igfJm per 24 hou ... l 
6.2.4 Type of death 
Type of death AIOS C""" 
Restleu , , 
Painful • • 
Wei chest and dyspnoea , 
VOI'MI,,\! • 
Doslreued " , 
Peac:elul H " 
Table 14: Tylltl of <lea1h 
501 the 29 AIDS pallent! died a painful death compared 10 0 caocel' patlenlS 










p" 0 02. I1ohe, IIOUC1 
6.2.5 Length of stay 
" OS c-
""- " •. , "- . , " .... ,..\lefltI " " 
Table 1$ L.ngth or ltoy .nd morph! .... dmlni.tr.lIan 
The IIverage length 01 "ay (55 and 59 days ~peCl"'(!ly) II $omilar lor the AIDS and cancer 
pa\ienl$ In lI'>e $tl.ldy 
~ _need .. lion ... ClIft! 





flbll 11 hlO'llhi ... IMImlnlltrltlo ... Ind plK' or Ur' (hO .... c ... o.ln·PII II,nl unit) 
Pc OOO1 , chlt'lI 
6.2.6 Trond of morphine administration in the in-patient unit over timo 
The study perIOd contisled 013 years and 5 month' and commenced In 2001 
'998 
,,,, 2000 200' . " _ .. • , , " 
,~. , • • • 
r~' , , • " 
Aid, fWT'\4 .. '" '" " .. 
, , • " 
• , • 
r • • , , • 
, ... , ... 
hbl. la : Numl>et or !>Ili.nla usl"11 morpN ... per I"'U 




Fll/U" 10: MO<p"'''' Mlmlnlll ... Uon dIstributed Il>tOugh the ~ea ... in Ill. 1'010 1I/'0U9S 
Ot.otlng 2001 , (T,bIe 18 and Fig,,", 10) change in Ittlll llde could be seen iI5 evidence In the resuKs 
HOI only did the Incidence 01 morphll\e admtnl51ered 10 AIDS !)abents Increase dramatically dur ing 
thIS year the numb« 01 AIDS pa\l&!lts who died 11'1 the in..patoent unit from AIDS also Increased 
Keep 1\ mind thaI tn,s study exduQefi the pell&lll$ wno died at nome It " not known If the trend III 
10 lhe Ir.-pallenl Un!! is lor uncontrolled symptoms_ 
6.3 Findings when factors are combined for relevance 
Thef ••• sla\lsliCally meill'llnglul dillerences 11\ the fil'ldlngS $hOwn betor. Tile k:IIowrng HCI>OtI ri 
look 1'1 dlllerenl combinatIOns of key meaJUr_nlS htghigllllrlg tI\e Intersection ItId NIItlOnStup 
bel\liee" II>em 
6.3.1 Doses of subcutaneous morphIne, sedatives used and type of deilth 
The roiowlng f8CIOlS ilnd trier! relabonSnopIlMI _loOked ill In dillerelll combtnatlDns 
MOI'p/OOe dose (duI'lng last 3 days) 
The subglOUP whO leee.ved mOl'~ lor lell lhan 48 hOul'1o (demarcated) 
SedaIlVe dosiIgH durrng 1a.1 24 houts 
SedillNe indrcallOll 
Type of dealn 
SymptOm. on ildmllllOl1 
6.3.1. 1 AIDS patients 
Dap Wor. delth L .... MId..:oIam ,,,.. 
AIDS . ..., "".-j[)o; ~ of de.M1) (d .. p) HM' 2<1 houri) """ 
PabenI number <>2 0-' 0 
'" 
, , , • P.acelul 
'" 
, , , , P .. eelul 
'"~ 0 
, , • ,-
'" 
, 0 0 • P~..,..fuI ". , 0 0 , PeacefU 
'" , , , H P, I""" 
'" 
, 0 , , ..... u 
'" 
, , , " , P~nlul 
''" 
, , , , " ''"'"'" 
'" 
, , , , " ....... 
'" , , , • " " .... 
'" 
, , , , ... .... u 
'" 
, , • " "~a 
'" 0 0 " 
, ".... 
'" 
, 0 " , .. "'" 
'" 0 0 " " P,lnlul 
'" 
, 0 " , ... -". , , N , " P~lnfu' 
'" 
, 
" " " """" 
'" 
, " " 
, '" "" .... 
H' , " " • :ZJ.7$ 
,....... 
In , " " , ,-, ,-~ 
'" 0 .. " , " ........ 
'" " " " 
, PelKelui 
'" " " " 
, ,..-
". " " " " 
, ,-
'" " " " 
, RII_ss 
'" " " " 
, R._p 
'" , .. , .. "" , Peaceful 
A_ ... ,., .. , '" ~ " 
Hurnl:ler on • " H mOfp/lone 
Table 19 AIDS p~".n"· SubGl>I~n.o". rno,p."nt docK ... .. d.t;~ .. and type .. 1 deatll. 
" 
5 
Morphln ' lor'" 48 ho ... O$ , 






4 (0 ') 
~----;S;''':::ltIV", 
II _ 11 
AI DS pal;enls u,lng morph ine for IHI thin 48 houri or none (""23) 
Flgu ... II : Yenn d i'Q<am 01 AJOS IH'I .. n~ ... tl ng mO'pll'lI4Ilo' I ... than (8 nou .... nd the Inl."..ctlon 
wllh ",unlul lyl'4l 01 ,Intn and ..... 11 ..... dm,,"",red durif'lg III, lUI 2~ 110 ...... . 
The doagrammallC IlluSln!UIOO .~cluclel the pori"", 01 AIOS patients (6 of the 29) who fl!<:l!Ned 
I"M)fpl\lne IOf I'I'I(lre then 48 tw;""", hom the morphille group 
, 01 1M 5 AIDS patlenls who receIVed 10 $t!dalNe and no morptune d ..... a paInful death -
noIeCI WIlli \' ') ,n tile $edmM!l group 
ot the 7 AIDS pa~enls Iha1 rec.rved 5I!dallon ,n CaljuroctiDn W11h morphne. 6 h<td bef!I'l 
" 
For !he comparawe lIIustralOOl1 lor the caoc:er pat,ents tna number that rece",ed morptllrle lor more 
than 48 OOllfS IS 21 AAnoll9h the ""'"bets in each grOUp I, ddferem, the pOillt beln\l illustrated ~ 





• 2 (. 2) 
'x 
~ 
Morphine for < 48 hours, SedatlY .. , 
,", ' " , 
Cancer p;otlenl, using morphine for In, t han 48 
!IOU", or none {n_ 81 
OIlunher note 
• 5 OUt 12 ( .~) 01 AIOS Pabenl$ whodod not recerye morphone receiVed sedallve5 
• 2 out. (SInIo) 01 cancer pa~ents whotlod not recente morphine, re<:e:ved sedalrves 
6.3.1.2 Csncer patients 
.......... - ""-~ I,M.ol'Olam T ... ~ ea- ... ""-(D~ ~ of deaIh) iQaysI 1'-12<1 I'Iours) --- -- -
Patient number 0-2 0-1 0 
'" 
, , , , 1.' ,-
'" , , , " " ....... 
'" 
, , , , ,-
m , , , , Pe~ul 
'" 











" " " ' .... TO' " " ., • --'" " " " , ,_,,, '" " " " " , .. , ... 
'" " " " 
, Pe..,.PuI 
-
'" " " ~ " Po!_lul - --'" " " " 11 Puuful 
'" " " 
., , w.l cnH/ 
-
21 ' " " .. , ,-m '" '" " • 1.' ".~" '" ,,, '" ., " P~aeel\.ll --'" '" '" '16 , ,-" --'" '" " '" , w.lCINI.I ". '" '" '" , ,-m r- 12C '" '" • Peaceful 
'" '" '" '" 
, 
" Peaceful ". "" '" '" 1 "e..:eful TO' '" '" '" " ."'" -
'" '" '" '" 1 ""<:eM 
'" '" '" '" 
, 
"~,, 
'" '" '" ~. 
, Pe_r..I 
-
'" '" '" '" " p_rul 
A~efage 15U '" . ,." " ,. " 
6.3.2 Combinations with the focus on sedatives used . 
No Sedation 
No Morphine 
AlDS 7 5 " 7 
2 2 23 2 
Tile p~1tems oIlfeatment for AIDS and eancer patll!fllS differ SIgOdlCBntly (pooO 008 F,shef exact 
lest) 
SymptOm, on admission - Typeol m'.-,- , .... ""- ,-- , .. e. .... • 
'" - "- ~.- " - , ... ,- , .... 
'" - ,nU.,.. I.or .. _ 7.' --- , .... .- ,-
m - ~, ... ,- • - ,- ,- ,-... 1== 
'" - -- Oxa<~"", , .• - ,- ,- ,-~-
'" - po_'''' ~.- U .... _.".... ,- ,.- ,-". -- -- -- " .... ;0 •• "" .. ''''*'' , "" jo, , "'.Iar ". -.... .... , ~.- " '""'" , "" 1<>< ,~- , .... ". -- -,. ,- • eon .......... I "'_\Or ,- , "'aj .. 
'" 1Q,,1&4 _otf"1 """".oIom 7.' .... 11 ......... 1 "" 1"" ,- .-
-" ", '_M " .. ohlloj ,,~ ". -- ,- ,M_ .-..,.,.. ~ , -
'" - ..... ""'"- " .... - ,- ,- ,----
'" -- - ' ...... '_" 2375 -_. ,- ,- ,-hbt. 22 1!ld1e.llon.klt ud.llves MId IrmptOtM on .cImi ..... n 
2 01 !lie S AlDS pa~ents who died a painful death recer,.ed sedation One (number 114) fecel~1!d 
5I!datIon because the fescue dose of morphine did not control pain In tillS pal1lcula, pauent 
ailhwgh morphll'la was prescribed .: days before death, it was ooly given 'as requued' on two 
OCC3S1Of15 befora she died On DO!I1 days ID and 0 ·1) lhe dosage was 10 mg pel" 24 IIour$ TlIl$ 
" 
CO!lSIS1W 01 on~ -rescue dose" 0110 mg morph:ne on eac~ 01 the two days. "Rescue dose" ,n the 
nursing notes In this case was a misnOMer as tile actual use In this situation was "as requlfed" 
6.3.3 Combinations with the focus on the type of death 
6.3.3.1 Type of death ; separated Into groups according to morphine usage. 
Type 01 dearh when separated Into groups 3<:cordlng 10 morphUlc usage 5 days bclQre dealh and 
day 0 1 death resp&INely 
r- Morphine ,S days Morphrne , 5 days AIDS 
belore death (0-5) 
C~ 
belore death (0-5) 
TVPI' of _ 10, Total 01 AIDS """- ~o mer""une TOlal of cane« MouIIIi"" ,,",0 mol'pr' lne plll<onl. P_ma 
Peaceful " 
, 
" " " 
, 
Re$lJe .. • , • , , , 
P .... luI , 0 , 0 0 0 
.... t cOOs! , 0 , , , 0 
I 
uncontrolled .OfJ\lMg 0 0 0 0 , 
TOlal " 
, 
" " ,. , 
Tabl. 23: Type 01 dUlh and morphine .dmini5Irallon: 5 days belore death 
Morphine. day of 
AIDS 
MorphIne , da~ 01 
c,~ 
dealh (D) death (D) 
TYI>! of aUlh TOIal al AIDS _'00 No motp'"'''' TOlal of C8~' MorP'><rIe No morphine palleMS Pallen" 
peacefur " 10(*9) , " " 
, 
restlesa • J 1*1) , , , , ---
painful , 3 (+3) , 0 0 0 
wet (:nea! , 1 I_ 1) 0 , , 0 
l.O\COIllf~1ed ..,mi!in~ 0 0 0 , 1 (. 1) 0 
TOla l " H " " " • 
(* n) • Of\C1ease 'rom 0 ·5 In p'e'llcu5 lable 
h"le ~4 Ty,,~ nj ,,~~, ~ ~n~ "''''Ph In" ~"m;nl" .... ""n· "' y "I de .. " 
rOt 9 of thl! 14 AIDS pat·ents ..... ho were .",hated on IIIOtplune durmg !he 5 days belore 
deattl a peaceful 6eath ..... as achoeved (14 IS the toIaI of the numbers In brllcltets in Teble 
'" 
Of the 5 AIDS pa!leOts who died II pa .. ful death none feuPVed morphIne '",e days before 
me" deatt> Althoogt> morphIne was In""'ted dose \0 deam lor 3 pilltenlS !he morphine 
admlnls\",:oon IOf the shor1 pellod did IlOl prl!Yefl: ~ 'rom dyIng a gainful death Two 
oa~nt$ d..:l no! ,ecetve any morphtne 
6.3.3.2 Type o f death: looking af sedation and morphine combined 








3 4 2 0 , 
1 1 1 0 0 , 
2 2 0 \ , 
00000 
o I) I) 0 0 2 
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NotICeable 1$ the absence 01 pa in as a symptom In the group 01 eancef Plllen:' ..... ho did 001 
d,e 8 peaceful death 
1' ..... 0 AIDS pauents dted a paInfu l dealh ..... ,lhool !he adminIstration of fI'IOIPhllle One 0I111e 
IWO recllIYed a sedat l~e 
1 h,ee AIDS patients died .. ,eslless death ..... 'thout beIng ;Jdmiru1lered it S&da:.ve Two 01 
the thfl!i! AIDS pat ,ents who dIed a restless dealh receoved morOMlne 
" 
6.3.4 Last 48 hours 
5eda\IVe1 wete lIdm,'hSlered on an'lIS re'qUlred" basis 10 12 OUI 01 29 AIDS pal.ents (4 1%) and 4 
OIA 01 29 cancer pallenls (14%) on the lasl 24 houNi 01 Ide For AIDS paltents 1 1 01 lhe 12 received 
erther no morphlOtl or morpimle lor leas than 48 hours (38 .... of A IDS paloenls) Of th iS 11 6 (21% 
01 aD AIDS pal~111 d,ed a f\OI1·peaceful death ne remaanlng A IDS pat,ent who receo\led • 
sedall~e. re<:elVed morphine lor Ihe last 120 hours 01 Ide 
2 caoc:er patoenls who rece,ved sedatlYes du"ng the lasl 24 holXS also received morphine BoIh 
,ece,ved morphlf\e Itr longCf lhan B days and average dosages 01 morphine was 113 mg and 231 
mg OVII' the IlISt B days of Me 
6.3.5 Length of stay and morphine adminis tra tion 
Lengel'! 01 stay (lIVI(ieS the t.me per;oos patients receIVed morphine .nto home care ood "'pa!lf!I1t 
Im' t tare 
6.3.5.1 AIDS patients: dous of subcutaneous morphine (or equivalent) 
o.~ bebo de.th ~, ,. ~, ~, D ' D 
I"atoMll "umbe r ,,. 0 0 0 
'" 0 0 0 0 0 " 
, 
'" 0 0 0 0 0 " 
, 
'" • • • " ,. '" , 
'" 0 0 0 0 0 " 
, 
'" 0 0 0 0 '" '" 
, 
on .. ., " " '" '" , 
'" 0 0 0 0 " .. • 
'" 0 0 0 0 0 " 
, 
'" 0 0 0 0 " '" , ". 0 0 0 0 " ., , 
" 0 0 0 " " " " , m " 0 '" '" '" "" "" 
, 
'" .. '" '" ., ., ., • 
'" , 0 , 0 0 '" " ". , '" '" '" '" " " 
'" 
, 0 0 0 " " " 
Numbe< or - ~ , • , • " " 
• Shllded .. "" ~s days ~ ., .... palloe<\l "ftd 
• Non ,.,...<kd ...... d,,_. d")'I spent undrr 110"", care lemce 
hbl. U ; t.ng1h 0' s~r of Aros pal,.nts nsoc ia'ed with morphine adminlst. ation. 
The PlMoeots who (ltd not recerye morphone are e~cIuOed 'rom tillS table 
4 -'lOS pattents (pallent rwmbenl 107 127,128 129) .ece<VN morphine before adm<ssKln to the m· 
PlMlE!t'lt 004 Pat en! number 107 does not qvahfy for 1hts category as morptune was started after the 
in.paIlen! unIt doctor was contacted, .edl.O'\g tile number to 3 The m",or.y (13 .numbel t07 " 14) 
tile cencer pauen! .. For 6 cancer patents mo.pl'm1fl therapy was indoated afte< admISSIOn 10 the in· 
p~ uRI! whilst tile balarce (20) .ecelYed morphIne before aomlsslOn 
6.3.5.2 Cancer patienfs,' doses of subcutaneous morphine (or equivalent) 
o~ belofe liN," ,., "' " " ,., , 
Pat .. nI numbef LIItIQIh 01 SIr! ,"", 
'" '" '" "" '" '" '" " 
"" '" "" "" '" "" '" ,'" '" '" .. .. .. .. , 
'" " " " " 
, " , 
'" " " " " " " 
, 
'" " " " " '" " 
, 
'" '" " " " '" " , '" , .. "" , .. , .. , .. '" , 
'" '" '" '" '" '" '" 
, 




" '" .. '" " • -
'" "" "" '" "" '" .. • n, '" "" '" "" '" '" • no '" '" " '" '" '" 0 
'" '''' '" 
,., 
"" "" m 
, 
n. '" ,~ "" , .. "" , .. , 
"" '" '" ,ro ,ro "" '" 0 "" "" '" '" ,ro .. '" , '" • " " " '" .. '" 
'" '" '" " " " " '" 
"" '" '" "" , .. "" "" '" '" " " " " " " " 
'" '"" '" '" '''' , .. .. I- " 
'" '" " " " '" '" " ,., 
'" '" "" "" 
,,, ~ " -----
N\>MDe' on 
" " " " " " -,~ 
n Sh~ aru dInotu doys """ .. "" In-p.tef'll uM 
n Non shade<l.",. denoteS d.y. """ .. under home ca,. OeM«!! 
TI"" 27 Lenglh o' ""V 01 UI\Cef ~,'-nt. "'Oclll"'" w,'h morphIne I<lmlnlst .. t!on. 
" 
6.3.5.3 Morphine staffed during home care versus in-patien t unit care 
AIDS elite., TolOl 
MoI'pnne S\arteO in Home care • " 
'-
23 
MoIphone started in In-pal>l!nt Unit " • " 
No morphine " • " 
''''' " 29 " 
Table 211: MorphiM s taRed dunng IIome care verous In.pa rlel1t "nil car .. 
FlStler exact test p .. 0 00" 
Tho! adm,$$1On 10 In-Pabeflt un~ IS 8$$ocrared Wllh a hoghef ,nc,dence of mo rphlOe adm W' 'SlrilllOn 
TIlr$ IS statIStically 1rffefent !Of AIOS and cancer paloenlS 
6.3.6 Symptoms present on admission to the in-patient unit 
6.3.6.1 Palienls on morphine 
FOO' lhe AlDS pabetllS 11 ClUt of 17 (65%) had pa.n as a map problem an(! fOf the cancer I)3berIIS 
12 OUI of 25 (.8'\10) had pain as a miljOf problem 
"'os - , 
p .... ROt • ",obi<:", , 
Absenl lorm1 0 
morphone ... " 
pa 01 nlll a prolllem , 






6.3.6.2 Patients who did not receive morphine 
LookIng alllle nU'$"'g chan completed for symptoms noted 011 admISSion Seel Table 31. (>'Ie 
nolic~ the fo/lowlng 01 12 AIDS patIents who dIed wlthoul recetvlng morphine. k was noted lhallor 
6 patienls pa:n was a malOr po'ob lem on admlSSron Fo. another 3 It was noled thai Ihey had 
dysphBglB although not parn, 4 had dyspnoea and lor 7 cough wa$ a major p.oblem Usrng 
morphine 100' dYspnoea reqwes c lrnoc:ai )\l(jgment as II may cause respiratory suppressIOn on 
pat>f!nt! who ar! a1 "sk for respor3tory fatlure 
Thus II 0lII of 12 AIDS patIents who dod no! rece""e morp/'lrr>e (75%) had pam raporlad and noted 
(rndudrng dyspOagla) In a major p roblem 
FOO'!he 4 C8I'I(:er pat>enll who clod nOl .eceNt mOO'pNne the symplom cllart was not comp~ted for 
one Pam was '101 recorOed as a problem for the remarnl"9 lrnee 
labl. 30; Srm~ pr_l.., adm ... I.., to tho ;n.paU.nt UNI lor .t.I DS ,rd Ca"".' p;oti.nls NDl on "'orpl'line 
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..:C-,-h",' ",p-"le",',--7,------=O-,isc u s s i 0 n • n d I nle 'P ,el.li 0 n 
TMe rely l!s demonstrate IhcIt thefe ill!: measurable aod ma.-~ed dilfef1!!'OCeS In ~ 
adm""strat>an b&tween AIDS and cance r patoents In the .,·paUent UM of 51 FranCIS HosP1C8 The 
d,llerence •• r" nctlCeobio In 
ProponlOO 01 patients belnQ gNen morprllne 
Average dosages of mOlpl\",e 
• Time of In~ l a\l()n on morph,ne 
• SedatIVeS 9'l<en ,n eoniunctoon With morphine 
• 11..11111,181 trends", morphine admlnlstraton 
Numb!!< 01 pallenlS tiling a patnlul death 
Symptom p<evalence on adm,sSIOO to the tn ·pat~nt Unit III pallen!! who were flO! O'ven 
m,.",,~ 
Summlfy of fll'ld.ngs 
FNe days beftlfe t/'ef day 0( dea~ {0-51. 3 (10'l10) d Ihe 29 AIDS pallents were grven 
morphine for pa.n eontrDl, 'eeeMl'l9 on average 120 mg pet 2" hours lief os Of the Ca'ICeI' 
pat.en:s 20 oIlhe 29 (69'l1o) recetved m«p/'one 1M! days tle/or. their day 01 death, \YlIh an 
average dose 01 151 rng per 24 I\ou's pel' 05 
• On the day ol llle" death (0) 17 01 the 29 (59'!1o ) AIDS patoents were g.ven I'I'IOIphonewllh an 
average dose of 39 m9 per 24 hours per OS For cancer pal;ents on the oay of deMh 25 of 
the 29 (86%) were 9'\Ief1 morplllOe WIth an _age dosage 0( 120 mill*' 2" I'«.Irs per CK 
11 (65%) 01 the 17 AIDS patoents gIVen morphll'le died Wlthon '-8 hours at COOlmenCIIIll 
morphine ttle rap1. tile average dose at morphine belllll'- "'9 4 hOurty pel os ( 16 mil pef 24 
hOuf5) Tile m;mmum dose (!;O mil pe< 24 hours) 1$ wM1ll1he re<:omrneoded $tartrrrg dose 
rallge for oplOld I18 lve·patoe<llS 
During the last 2~ hoor$ ~edatl~e~ were adm"'s!ered 10 12 AIDS patients 7 reeeiVed 
morph ine as weU and 6 of the 7 AIDS pabenl1 rectived morphine for leSs !nan 48 hours Of 
the 25 cancer pallent~ 9 ,~en morphine. 2 al$O recerved sedat l\'e$ during !he I~t 2~ houri. 
and 4 of !he 25 were 9 ven morphIne for leu thlln'-9 hours 
Of tile 5 AIDS pahents (17%) who died a painful death. two dod nOi receIVe morphine at all, 
and J pa~ents were gIVen morphil1e a few hours oofore thair death 1 of the 3 AIOS patients 
lecelVed a seda llve as we ll No C3ncer patients dlf!d a pa inful death 
• From 1998102001 Htele was a marlc:ed increase In Ihe propotlion of dying AIOS patients 
De lng g iven morph ine from 0% to 100'4 
7.1 Sample profiles 
The 29 pailent! who died from AIOS rela~ed diseases OVef a period of 3 yea,.; and 5 months In the 
In-pallent UnI! IS a sma ll number of the total pat lems cared for over the same ~me penod The 
average iI1'palient urn; admiSSIon l ale Is about 24% pel year (refe r Table' on page 22) and \l'Ie 
average pat,ent foad Is about 800 patients per year Some AIOS and cancer patients are discharged 
home whilst others d ie ,n In-patien! ullll My i<npresslOn from work ing on the in'pat,enl unit was that 
more than 50% of palients ildml1led d,e In the In·paloent unit and less than 50% are discharged 
horre No data are available to substant iate my .mpressoon 
AlOS pa ~ems '998 '999 2000 200, rOU' 
Total number cared for 71 155 ", 533 98' un-pat,ent Un,t and home) 
Number d,e(! In In-pahent 
2(+1)' 7(+2) 8(+3) 12(+4) 39 
Un~ 
Number "'" In In ' pat,ent 4.2% 5.8% 5% " 3.'" UMas% 
lablo 33 . .... OS deaths In in-poti. nj ,,,,i, uprouod ... po","nuge 0' ",10S ~'i .. nts cared for 
The proporlfon of AlOS paloents dy,ng on the in-pat ent Uno! (3.9%) seems very low However, [h iS Is 
not a conventfona l death rate the denorninalOf is the numbel cu rrently ca red lor, IIOt the tOlal 
numbel of pa!ienl~ dying w.th NOS Although hospice patients Wllh AIDS may live longer than 
hosptCf! cancer patients ,t does ra,se the suspic ion that a disproportionate number of NOS patoents 
• fIg"'o" "'><> ... ""'''' .... til. n"",he< 01 p.,.,n"..no _re ""o1u<Ied kom lor "'."""Y bu, die<!" "' •• PU ''''''''9 1M 
''"<II' por"" 
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The In.pa11ent unit seNes the home care populations (both AIDS and cancer) for whom symptom· 
contro l becomes challeng ,ng and' or family resplle is requ ired The need for family resp 'te IS often 
an IndICation of symptom exacerbatoon or entenng 01 the dying stage 
In th iS study the average AIDS pallen! was younger than the average cancer panent ThiS conr,rms 
repo<lS tha1 AIDS IS a disease Iha! allects young adu lts people establishing lamll ies and a 
potentially economocally actNe section 01 the populat,on. 
The ethnIC group representation 01 Ihe AIDS patients in Ihe study is comparable Wllh that 01 the 
country· Black 752%, While 13.6%. Coloured 66%, Indian 2.6%. The p,IOt study showed b'as In 
the caocel control group towards White "medica! a.o:r pa1l1!nls!I e With pnvate medocal lnsurance) 
The recogrntoon 01 bias led 10 a change In select!on cr[tena in order 10 select a more SOClO-economlC 
and ethnlCalfy matChed control group of cancer patoems 
7.2 Main findings 
The vooced op,noon 01 the nurSing stalf that set th<$ Siudy In mOhon, that the majQrlty of AIDS 
pallents die within 2 days of beong slarted on morphine Is valid The concern about lhe reiallOn of 
the deaths to morphine admlnlstrat<on IS .. mderStandabie Such an ImpreSSion would be harmlullo 
the Image of hospoce The queslions that ilfOse .... ere . Would these patIents have died regardless 01 
lhe administration of morprnne? Or did Ihe morphine adm,n isHal,on influence the" l ime of dealh? 
From IhIS, 2 hypotheses in the conteXI of pain control were OUI fOlWard 
Pa in has 10 be recognized antJ assessed before It can be Ireated e 9 morphme can be 
admlnlS1ered fOf pe 'n mtln&gement If p.,on 1$ not re~Ognlzed. II w ~1 not be treated. If 1he'e 1$ 
eviderlCe Ihat a greater proportion 01 cancer pahents (compared 10 AIDS patients) received 
morphine and a sma lle< prOpOrtIOn 01 cancer palients died a pa inful or less distressed 
death. tht! WIH suPpOrt the hypothes's that palM In AIDS pa1ients is u!1der·recogruzed aod 
under-trealed 
If oPKIlds and/or sedatIOn are administered to HIV·posltive pat'enlS in such a way thilt death 
is hastened, there WIU lie ev>deflCe 01 them reeelVlng dOsages abelle the usual 
recommended range Close to lrle lr t,me 01 dealh 
It was "",portant to obta in Clarity on tM actuality of the Situation ror the reason of ensuring that 
pallenlS receive symptom rehel withou l bias or prejudices 1\ is not hospice policy 10 haSlen death 
.. 
Neither is it hospice policy to leave symptoms such as pain (and therefore suffering) untreated. In 
between these two extremes, lies an uncomfortable compromise as far as refractory symptoms are 
concerned when high dosages of drugs (usually sedatives) are required for relief. The moral conflict 
between the desire to relieve suffering and the duty to avoid killing is (to some extent) resolved by 
the doctrine of the double effect. 25 The concept of the doctrine of the double effect "allows· for 
symptom-control (usually by mode of conscious sedation) at the risk of shortening the life of a 
patient. This concept is controversial and it is not the intent of the study to address this concept 
directly. 
The actual differences noted in morphine use will be discussed and interpreted to show that the 
underlying reason why the majority of AIDS patients die within 28 hours of being started on 
morphine is a manifestation of under-treatment of pain in this group of patients. The bulk of the 
evidence obtained was objective and not influenced by subjective interpretation. The risk of 
systematic bias in data collection is small. It reflects the situation of pain management by recording 
the administered drugs according to the medicine charts. Evidence, such as type of death and 
symptoms on admission, although subjective in nature, also supported the theory of under-
treatment of AIDS patients. 
There was no objective or subjective evidence to support the idea that death was hastened due to 
morphine administration. 
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7.2.1 The number of patients on morphine for pain relief 
When AIDS patients are admitted to the in-patient unit from the Home Care Service (see Table 26), 
10% were using morphine for pain control. This contrasts sharply with the data for the control group 
of cancer patients and practices reported in the literature. 23.34. St. 73. This single piece of 
evidence is the most significant finding in support of the under-treatment theory. The difference is 
statistically significant, with a p value of < 0.001. 
It is to be expected that towards the end-of-life, an increase in pain and therefore an increasing 
need for analgesia would occur in both AIDS and cancer patients. The study by Breitbart' confirms 
this. I would further expect that the increase in pain (and accompanying analgesia required to 
control it) would be noticeable before the last week of life. 
There are few studies on the prevalence of pain as a symptom in the last week of life in people with 
AI DS23•43 , and reports of the prevalence of pain in the general AIDS population (ambulatory and 
hospital) vary between 28% to over 93%. 10, 12, 23, 27, 21, 43, 41, 47, SO, 13, so. It has been reported that pain 
is more common in advanced disease.' The etiOlogy of pain in AIDS patients can be attributed to: 
1. damage from HN, 
2. co-infections or tumours, 
3. treatment (of HIV, co-Infections and tumours) or 
4. unrelated causes. 
Neuropathic pain (mainly in the form of a peripheral sensory neuropathy in HIV patients) occurs In 
10-20% of patients. Causes are HIV itself or treatment-related (anti-TB and anti-retroviral 
treatment). Neuropathic pain is only partially responsive to opioids. 
KimbaU43 reported that of 88% of AIDS patients in Seattle in a hospice setting who experienced pain 
during the last two weeks of life; 93% received opioid analgesia (0.93 X 0.88 = 82% of total patients 
in study). No comment was made on serial values of opioid administration. In Rome in an Infectious 
Disease Hospital wards and day Clinic Fantoni23 reported a 68% prevalence of pain as a symptom 
during the last week of life of AIDS patients. Opioid analgesics were used in 28.6% of patients in the 
week before death and in 19% of patients 3 months before death. Fantoni's study covered the 3 
months preceding death in AIDS patients and reported equal prevalences of pain as a symptom 3 
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months before death (60%) and at one week prior to death (58%), although the opioid (and non-
opioid) administration increased from 19% to 28% respectively. There was no mention of pain 
intensity or severity. In a 2 year study in Denmark (Copenhagen) in a Department of Infectious 
Diseases, Frich21 reported a contrast in incidence of opioid use in AI DS patients of 39% of all 
patients during the 2 year study period against 69% of patients who died from AIDS in the unit (27 
on opioids out of 39 total, died in unit). Not all patients in this study were terminally ill. 20 were alive 
at the end of the study (n=95). 
General AIDS population studies (not tennlnally III patients exclusively): Breitbart, in a 
prospective cross-sectional survey of 438 ambulatory AIDS patients in New York City,' found that 
63% of AIDS patients reported frequent or persistent pain of at least 2 weeks' duration at the time of 
assessment. The prevalence of pain in this sample increased significantly as HIV disease 
progressed, with 45% of AIDS patients with category A3* disease reporting pain, compared with 
55% of those with category B3 disease, and 67% of those with category C1-3 disease. AIDS 
Patients in this study also were more likely to report pain if they had: 
• other concurrent HIV-related symptoms (eg, fatigue, wasting), 
• had received treatment for an AIDS-related opportunistic infection, or 
• had not been receiving antiretroviral medications. 
In a French multicenter study by Larue and colleagues,'" 62% of hospitalized patients in France 
with HIV disease had clinically significant pain. Breitbart and colleagues' reported that ambulatory 
AIDS patients in their New York City sample reported a mean pain intensity of 5.4 (on the 0-10 
numerical rating scale of the Brief Pain Inventory) and a mean "pain at its worst" of 7.4. As with pain 
prevalence, the intensity of pain experienced by patients with HIV disease increased significantly as 
disease progressed. AIDS patients with pain, like their counterparts with cancer pain, describe an 
average of 2.5 to 3 concurrent pains at any given time. Less than 8% of AIDS patients in the 
Breitbart study' reporting pain in the severe range (8-10 on a numerical rating scale of pain 
intensity) received a strong opioid, such as morphine, as recommended by published guidelines 
such as the WHO analgesic ladder. The 8% reflects all categories of patients with AIDS and not 
exclusively on terminal patients. In addition, 18% of patients with 'severe' pain were prescribed no 
* Centers of Disease Control and Prevention, 1993 revision of AIDS Surveillance Case Definition for Adolescents and 
Adults. This Is the classification system used when CD4+ counts are available. 
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analgesics whatsoever. Utilizing the Pain Management Index (PMI), a measure of the adequacy of 
analgesic therapy derived from the Brief Pain Inventory's record of pain intensity and strength of 
analgesia prescribed, Breitbart further examined adequacy of pain treatment. Only 15% of their 
sample received adequate analgesic therapy based on the PM\' This degree of under-medication of 
pain in AIDS (85%) far exceeds the 40% under-medication of pain (using the PMI) in cancer 
populations reported in other studies.14 
One may argue that comparisons are drawn between 1 II and 3111 world countries. The similatity of 
experiences of cancer patients (see following section) to those of 1st world countries would then be 
discrepant. 
7.2.2 Increase in numben. of patients on morphine during the last 5 days 
In St. Francis hospice 3 (10%) of terminally ill AIDS patients were using morphine 5 days before 
they died; 17 (59%) were using morphine on the day they died. This is an increase of 470% over 5 
days. The group of cancer patients had a 25% increase in patient numbers using morphine (from 
20 to 25) during the last 5 days of life. Despite the large increase in AIDS patients given morphine 
during the last 5 days, there were still statistically significantly more cancer patients on morphine on 
the day of their death. This is evidence that under-treatment of pain in the AIDS population under 
the care of St. Francis hospice was a frequent occurrence during the study. 
The data on pain management in cancer patients at st. Francis hospice compares well with studies 
elsewhere with cancer which report that between 70 and 89% are receiving morphine during the 
last week of life. M, H, 73 
In London In II hospice setting, Thoms73 reported an increase of morphine administration (from 
61% to 89%) for cancer patients during the last week of life. This study shows a similar trend for 
cancer patients. An increase of morphine administration from 69% to 86% for cancer patients was 
noted. 
Compared to the 10% morphine use 5 days before death, a 59% analgesic use in AIDS patients on 
the day of death corresponds more favourably with practices reported in the general AIDS pain 
literature (between 30% and 82%) although it was still statistically significantly different from the 
experience of cancer patients at St. Francis hospice. By this I do not imply that the prevalence of 
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pain is necessarily the same for AIDS and cancer patients. It is difficult to validate actual differences 
in pain prevalence and pain intensity measures between AIDS and cancer patients as the widely 
reported under-recognition and under-treatment of pain in AIDS patients biases the data for AIDS 
patients to their disadvantage. Larue44 in a French national survey demonstrated that AIDS patients 
being cared for by a hospice at home had pain prevalence and intenSity rates comparable to, and 
even exceeding those of cancer patients. 
7.2.3 Morphine dosages 
7.2.3.1 Last 48 hours 
Table 11 shows that for the AIDS patients using morphine at time of death, 11 of 17 (65%) were 
started on it during the last 48 hours. The maximum dose for both groups was 50 mg per day. The 
average daily dosages of morphine commenced during the last 48 hours were 24 mg and 32 mg 
per 24 hours for the AIDS and cancer patients respectively. (for AIDS patients the average dosage 
is % of that of cancer patients.) Authorative textbooks'l.Io recommend commenCing opioid naTVe-
patients on morphine dosages ranging between 30 to 60 mg per 24 hours per os, divided in five to 
six dosages. The starting dosages in both the AIDS and cancer groups in this study fell within this 
therapeutic range. It is unlikely that these dosages could have been the cause of, or a major 
contributor to deaths in study patients. 
7.2.3.2 5 days or more before death 
The morphine dosage of the 3 AIDS patients (10%) who received it for 5 days or more before 
death, compares reasonably well to the morphine dosages of cancer patients receiving morphine 
for 5 days or more. Average dosages were 120 mg and 151 mg per 24 hours for AIDS and cancer 
patients respectively. 
Three of the 29 cancer patients (10%) received morphine at dosages of more than 300 mg per 24 
hours. A survey of hospice care practices in Israel2 demonstrated that 12% of the patients required 
morphine at a dose of more than 300 mg per day. A similar study in Japan" reported a figure of 
7%. No AIDS patients in this study received morphine at dosages higher than 300 mg per day. No 
literature studies for AIDS patients were found on this topiC. It takes time to reach stable therapeutic 
dosages of morphine of over 300 mg per 24 hours. Tolerance needs to develop and this usually 
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happens over a period of months. I suspect that the different patterns of morphine dosages seen in 
Table 19 and Table 20 between cancer and AIDS patients may be partially explained by the length 
of time morphine has been administered. Data to explore this hypothesis were beyond the scope of 
this study and were not collected. 
7.2.4 Duration of morphine therapy 
The study results show a shorter duration of morphine administration to the AIDS patients which 
was to their apparent disadvantage (Figure 9). The average number of days that AIDS patients 
were given morphine was 1.6. This is significantly different from 4.5 days for cancer patients 
(maximum n=6). The difference in time that morphine was given was evaluated over a 6 day period 
only. It raises the question of what the differences are over the whole period of hospice care, 
including the portion of patients that die without being admitted to the in~patient unit. In contrast, the 
average length of stay (5.2 and 6.3 days respectively) is similar for the AIDS and cancer patients. 
The data confirm the impression that morphine is given too late in the progression of the illness of 
AIDS patients. It also shows a relative advantage for AIDS patients admitted to the in~patient unit. It 
is more likely that morphine will be started if AIDS patients are admitted than if they remain under 
home care exclusively. 
7.2.5 Morphine usage in context of the total hospice service 
29 of the 39 AIDS patients that died in the in~patient unit were included in this study. 3 of the 29 
AIDS patients received morphine before admiSSion to the in-patient unit; another 14 were started on 
morphine therapy during their stay in the in-patient unit 
The pattern is different for the cancer patients: 23 received morphine before admission and for 6 
patients morphine therapy was started after admission to the in-patient. unit. 
Between 3% and 5.8% of AIDS patients being cared for are admitted, compared to admission 
figures of between 22% and 30% of the general population cared for by St. Francis hospice. The 
population of AIDS patients cared for by St. Francis hospice increased from 12% to 49% from 1998 
to 2002 - see Table 1. Of the small percentage that died in in~patient unit, only 10% received 
morphine before admission to the in-patient unit. The question ariSes about what happens to pain 
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control in the balance of AIDS patients in the care of St. Francis hospice that die elsewhere (about 
96%). It seems plausible to assume that they will have the same or even a lower prevalence of 
receiving morphine than the population represented by admission to in-patient unit. 
7.2.6 Sedative administration 
In palliative care sedatives are mainly used to reduce suffering (see 2.3.2 page 23) by lessening 
awareness of symptoms (refractory to standard treatment) by intentionally clouding 
consciousness. II Sedatives may contribute significantly to reducing suffering when chosen 
appropriately for the specific combination of symptoms in conjunction with a multidisciplinary 
treatment approach to underlying causes of suffering. A statistically significant greater proportion of 
AIDS patients than cancer patients were given sedatives. A possible explanation for the different 
prescribing patterns is that sedatives were used to control symptoms for which morphine could 
have been tried first AIDS affects a younger age group, more socio-economic problems are 
present, stigmata and lack of community support are also associated factors. 
Clouding of consciousness implies less awareness and function-in-life and it will detract from 
quality of life if symptoms could be controlled by other means while maintaining a more alert state of 
consciousness. 
For symptoms to be labeled "refractory" and to consider sedation in order to control the "refractory 
symptom(s)", we consider it involves the following: 
1. patients are terminally ill with advanced, incurable disease 
2. they are "actively" dying (death is expected within hours or days - judged from blood 
pressure, pulse, respiration, urine output, and level of consciousness 
3. acute or refractory symptoms such as pain, nausea, myoclonus, restlessness, or 
respiratory distress are present 
4. these symptoms have not responded to conventional management 
5. the severity of the symptoms and trajectory of the illness requires prompt intervention to 
relieve distress 
6. sedation is chemically induced, using a non-opioid drug. 
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Looking at this present study, the symptoms (of pain, cough and dyspnoea) present In the majority 
of AIDS patients can not be labelled refractory for the Simple reason that enough time has not been 
available for the triat to demonstrate the failure of conventional management of the relevant 
symptoms. 
Sedation was not used in the in-patient unit as generally understood in hospice care, namely 
conscious sedation, by the continuous administration of sedatives to alleviate symptoms. In a study 
at Sir Michael Sobell HouseN it was found that the dosages of SC midazolam for continuous 
sedation purposes was as follows: Starting dose was betWeen 20 and 30 mg per 24 hours (with 30 
mg per 24 hours as the recommended starting dose) and between 30 to 60 mg per 24 hours 
continuously as the common range for maintaining sedation. 
This was not the case at St. Francis hospice. 
Sedatives were administered on an "as required- basis to 12 out of 29 AIDS patients and 4 out of 
29 cancer patients in the last 24 hours of life. The dosages administered were well within the lower 
therapeutic range (averages of 7.9 mg and 7.5 mg per 24 hours for AIDS and cancer patients 
respectively), and below the therapeutic range for "conscious sedation". It is unlikely that the 
dOsages used contributed to death, even in the group of patients who received morphine for a 
period of less than 48 hours (6 AIDS patients and 0 cancer patients). When morphine is started, 
one of the side effects is sedation. Apart from this effect of the first few days of morphine treatment, 
additional sedation was required in a substantial percentage of AIDS patients. This is described in 
the next section. 
7.2.6.1 Combination of morphine and sedative administration 
When sedatives given to AIDS patients on morphine are looked at in context of the duration and 
dosage of morphine administration, another noticeable difference emerges. 6 of the 7 AIDS patients 
who received both morphine and a sedative, received morphine for less than 48 hours before their 
death. Another 5 received no morphine. This equates to 38% (6+5 =11 of 29) of all the AIDS 
patients in the study. Of the 7 AIDS patients on morphine that received sedatives, 4 had been 
started on morphine in the last 48 -24 hours, 2 in the last 24 hours and 1 in the last 120 hours. The 
nursing notes did not mention any patients in the study being over-sedated or showing signs of 
opioid related side-effects. For 2 patients with symptoms of restlessness and 1 with anxiety, a 
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peaceful death was achieved with the addition of a sedative to morphine (Table 24). For the 
remaining three (3 of 29 = 10%), the combination did not change the outcome of their death (1 
painful, 1 restless, 1 wet chest). For patient number 114 (who died a painful death, received 
morphine and a sedative) morphine was prescribed for regular use 4 days before death, but only 
administered in 2 prn dosages, one in each 24 hour period before death. This was incidentally 
noticed; similar data were not collected for other patients. 
The 2 cancer patients who received sedatives (together with morphine) were on higher dosages of 
morphine for longer periods of time (120 mg and 240 mg per day respectively) than the group of 
AIDS patients. 
It appears that sedatives were used to control symptoms in a group of AIDS patients when there 
was inadequate time available to control the symptoms by regular titrated administration of 
morphine. The same scenario is not noted with cancer patients. This supports the impression that 
pain as a symptom was recognized far too late in the dying process of AIDS patients. By the time it 
was recognized and treatment started, sufficient time was not available to control symptoms before 
death occurred, necessitating the use of sedatives. 
7.2.7 Type of death 
Type of death as a measure is not as objective a measure as morphine dosage. It relies on human 
subjective interpretation of the clinical notes, which in itself is a subjective perception and 
interpretation of the actual situation (see Figure 5). This may produce a more distorted reflection of 
symptom-control in general than morphine dosage which is objective and more symptom-specifIC. 
• 5 AIDS patients and 0 cancer patients died a painful death. 
• 6 of the 12 AIDS (and 1 of 4 cancer-) patients who received sedation died a non-peaceful 
death. 
With morphine being prescribed to only 10% of AIDS patients before their death, it is expected to 
observe pain preceding death and is corroborated in this study. 
7.2.7.1 Combination of morphine, sedative and type of death 
Of the 5 AIDS patients (17%) who died a painful death, none received morphine for the 5 days 
preceding their death. Two patients who died a painful death did not receive any morphine at all. 
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Although morphine was started close to death for 3 patients who died a painful death, this did not 
prevent them from dying a painful death. All 3 received morphine for less than 48 hours preceding 
death. 2 of them had been in the in-patient unit for longer than 10 days. 
This finding adds weight to the conclusion reached before that pain as a symptom was not 
recognized and therefore not treated timeously. It appears that morphine therapy was initiated too 
late during the stage of illness for AIDS patients to improve quality of life Significantly. 
7.2.8 Change of trend over time of morphine administration in the in-patient 
unit 
A number of discussions about morphine administration and its Side-effects in AIDS patients were 
held with staff Since January 2001. Being made aware of the literature seems to have put the issue 
of inadequate pain control in HIV patients to the fore and changed prescribing and administration 
habits in the in-patient unit during 2001. Although a larger number of AIDS patients received opioids 
during the last few days of their lives in 2001, it is unknown if any change occurred in the home care 
section of the patient population cared for by St. FranciS hospice. 
I seldom recommend a follow up study to look at current practices of pain management for AIDS 
patients in the in-patient unit. 
7.2.9 Pain control in home care unit 
Between 7% and 10% of AIDS patients had been started on morphine before admiSSion to the in-
patient unit. See Table 26 on page 22. This is a low proportion in comparison with practices in other 
Similar AIDS palliative services. 23,43 
I therefore recommend a study to look at the morphine use for AIDS patients in the home care 
system for a period of 3 - 6 months before their death. 
7.2.10 Symptoms present on admission to the in-patient unit: 
A symptom form is completed on admiSSion and the quality varies according to the staff members 
completing the forms. It was noted from entries of cancer patient who were on high doses of 
morphine, that in some cases, although the pain was controlled, pain was marked on the form as 
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"4. major problem-. From this it is reasonable to interpret the symptoms on the chart as valid only 
for patients not receiVing morphine on admisSion to in-patient unit. - symptom-control for the 
specific symptom not attempted yet. 
Twenty AIDS patients had pain recorded on admission with only 11 (i.e. 55% of those with pain) 
receiVing morphine. This compares to 12 patients with cancer who had pain on admission, with 
100% of these receiVing morphine. 
For 12 AIDS patients who received no morphine on admiSSion, it was noted that 9 out of 12 (75%) 
had pain (including dysphagia) reported and noted as a major problem. For 4 patients dyspnoea, 
and for 7 cough was a major problem. For the 4 cancer patients who did not receive morphine, the 
symptom chart was not completed for one. None of the remaining three had pain as a major 
problem. 
The high incidence of pain reporting amongst AIDS patients confirms the impression that pain as a 
symptom is not considered of a similar priority as in cancer patients. The prevalence of symptoms 
also favours the original idea that pain as a symptom is not given adequate recognition (in 
preference to the alternative idea that death may have been hastened due to medication). 
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7.3 Concluding interpretations 
7.3.1 Under-treatment of pain 
The starting point of the study was to look at pain control and evaluate two statements: 
• Death is hastened in some AIDS patients by the use of morphine 
• Some AIDS patients die without adequate analgesia (probably because pain is not 
recognized) 
The second view has been validated, namely that of under-treatment of pain in AIDS patients at St. 
Francis hospice on admission to the in-patient unit. 
Clarity was achieved by evaluating the management of pain at St. Francis hospice within a larger 
context of pain management and of palliative care principles. Cancer patients were used as a 
control group. 
A contrast is shown between pain control in cancer and AIDS patients in the in-patient unit of St. 
Francis Hospice. The situation of cancer patients correlates with that of 1st world counties and 
clearly shows the ability of St. Francis hospice staff to manage pain effectively near end-of-life in 
order to reduce suffering. 
Although mechanisms are In place to recognize and treat pain In patients cared for by St 
Francis hospice, this did not happen In the AIDS population that died In the In-patient unit 
during 1999, 2000 and 2001. Only 10% received morphine 5 days before they died. This 
fonns a starlc contrast to the experience of cancer patients as well as accepted "best 
practices" In hospice care. 
It is unlikely that AIDS patients in the Eastern Cape region are less symptomatic than AIDS patients 
in the rest of the world. A more likely explanation (for the 10% incidence of opioid usage 5 days 
before death) is that pain is not recognized and therefore not assessed and treated. The 470% 
increase of AIDS patients being administered morphine in the in-patient unit during the 5 days 
preceding death (from 10% to 59%) could be attributed to the fact that pain was identified as a 
problematic symptom only during the last week of life when an attempt was made to control it. This 
figure, although showing a marked improvement, is still far from satisfactory. 
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Good clinical decision making requires ongoing learning & reflection: 
• regarding the best interests of the patient 
• based on the balance of benefits and burdens weighed up against available evidence 
• within resource constraints (distributive justice). 
7.3.3 The role of objective evidence in bringing to awareness unrecognized 
issues 
• The impression of the connection between death within 48 hours and morphine 
administration in AIDS patients has been validated. 
• The subjective view, that death was possibly hastened by the administration of morphine, is 
not supported by the evidence gathered. 
• Objective evidence showed under treatment of pain in AIDS patients at St. Francis hospice. 
The unsubstantiated views played a role in the origin and maintenance of the problem. Fortunately 
the ·view taken" was voiced by a number of nursing staff. This allowed for the collection of evidence 
of this study and availed a mechanism to enhance awareness of the actual situation. With objective 
evidence available, (lack of) treatment of pain can now be recognized and viewed in perspective. 
Now that the actual cause of the problem has been identified and clarified, it would be relatively 
easy to remedy. St. Francis hospice will thus be enabled to truly care for patients the way they are 
known and respected for in our community. 
7.3.4 Questions that arise 
When the evidence of how morphine was used is looked at from the larger framework of pain 
control in palliative care, this study clearly shows severe under-treatment of pain in in-patient unit 
AIDS patients of St. Francis hospice 5 days before they died (p < 0.001). 
Questions that arise are: 
• What is the situation at other hospices in South Africa regarding pain control for terminal 
AIDS patients in their care? 
• How can the hospice system adapt itself to continuously improve the quality of care it 
provides? 
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Chapter 8 Recommendations for further studies 
The following studies are recommended for further study: 
Clinical studies: 
• A study to compare the use and non~use of a daily self-assessment of pain! anguish -faces 
of pain" scale, and its influence of this daily exercise on pain recognition and management. 
• A follow up study to look at current practices of pain management for AIDS patients in the 
In~patient Unit at St Francis Hospice. 
• A study to look at the morphine use for AIDS patients in the home care system for a period 
of 3 - 6 months before their death. 
• Similar studies at other hospices in South Africa regarding pain control for terminal AIDS 
patients in their care. 
Managerial study 
• A behavioural study to determine how the hospice system can adapt itself to continuously 
improve the quality of care it provides. 
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Chapter 9 Conclusion 
The disgruntled dead cannot voice an opinion from their graves. The families of the AIDS. patients 
are in an extremely vulnerable and dependent position. Having very few places to turn to for 
support, they are not in a position to risk alienating what little support is available by negative 
statements and complaints. 
In a country with limited resources, inadequate infra-structure, a signifteant level of illiteracy, and a 
government that is unsure about the cause of AIDS, we find ourselves faced with an epidemic that 
is causing enormous suffering. Hospital beds and nursing staff have not increased, although 
increased admissions are required to treat the rising number of patients with TB and other 
opportunistic infections associated With HIV-positive patients. This produces an increasing burden 
on a shrinking pool of health care services that deals with disease. The needs of the patient in the 
process of dying from AIDS is absent from the above scenario. 
HIV-positive patients are often denied investigations or treatment when they present with potentially 
reversible illnesses. On the other hand, inappropriate investigations and futile treatments should be 
guarded against as it not only wastes valuable resources, but may also detract from quality of life. 
With prompt recognition of symptoms such as pain and good supportive care, people with AIDS 
may enjoy a good quality life until they die. This approach has to be actively pursued. 
Unrecognized and unrelieved pain equates with poor palliative care practices as it does not 
contribute to quality of life. It contributes to the burden of suffering in an already overburdened 
section of our population. The good we can do in the AIDS epidemic is adequate palliative care. In 
South Africa palliative care is at present largely associated with a few hospices. Recognizing and 
relieving symptoms in the terminal and pre-terminal patient is of utmost importance for a successful 
palliative care service. Barriers to symptom-control should also be recognized early, and pro-
actively addressed. Unrecognized pain is a formidable barrier to overcome. 
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Appendixes 
Appendix 1: Consent 
Sr. Lesl� Lawron & personnel 
St· framtis Hospice 
Po.8ox779l, 
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Tel:(041) 56'6 25'!"9 
fax: (P4 l) 3�6 1565 
The'topfc I WQUJd like �do my research 01"i for·� Me$ter'$ � '11\,Rallialive c_ar,;t 1$: �id US& in 
the last week ofHfe. I have d•igned an applicable datlbase and am ready lo enter data. 
I would like to start with data (or 1 month at fil'St Coutd you provide me with:: 
1. a list of patients who died during May 2001 On the ward or at home) and 
2. their files.
t WE>!alld appreciate �oVr c:<)Qperation and $upport in th'iJ l'1'!aftet. 




Informed Consent for research by Dr. R Els at St. Francis Hospice, Port Elizabeth 
Preamble 
Progress In medicine and in health care is contingent upon the conduct of health and medical research, 
including retrospective epidemiological studies, which must be based on information concerning the health of 
individuals, communities, and societies. In many if not most cases, the information required for such studies is 
of a non-identifying nature. 
Title: 
A retrospective review of strong opioid use in the last 5 days of life of patients with HIV/AIDS or cancer at St 
Francis Hospice. 
Purpose: 
• The study will describe opioid use during the last five days of life with the aim of determining whether
differences exist between cancer and AIDS patients.
• This information will attempt to identify and quantify the differences, if they exist
• It may suggest ways to further assess, address or explain differences. For example, attitudes may change
when made aware of differences or methods used by clinical staff to elicit symptoms may improve.
• It may also contribute to ideas for further studies that may attempt to clarify underlying reasons for the
findings.
• Deficiencies in the data in routine patient records will be documented and suggestions for improving
information necessary for patient care, clinical audit and research will be made
Duration: 
Material will be collected for the calendar years of 2000 and 2001. Data for all AIDS patient deaths in the In 
Patient Unit will be collected as well as the subsequent oncological death. 
The processing of the data will occur during the calendar year of 2002. 
Ethical approval: 
Ethical committee approval must be obtained for all research studies 
Transparency and openness: 
Policies, practices and procedures relating to health information must be transparent so that patients can clearly 
understand the extent and purpose of health information collection, use, disclosure and access. These must be 
explicit enough that the patients are adequately informed and able to acquire knowledge germane to their 
confiding of information, and must also be open to scrutiny and challenge. 
This Research Protocol was submitted to the Research Ethics Committee of the University of Cape Town and 
written approval is awaited. The study has been structured in accordance with the Declaration of Helsinki (last 
updated: October 2000), which deals with the recommendations guiding doctors in biomedical research 
involving human subjects, a copy of which may be obtained from the investigator should you wish to review It 
Confidentiality of records: 
Computerised data will be kept secure (e.g. pseudo-anonymised, names will be stored in one file, number and 
personal data in another) 
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